Note: Descriptions are shown in the official language in which they were submitted.
ALBUMIN FORMULATION AND USE
Reference to a Sequence Listing
This application contains a Sequence Listing in computer readable form.
Background of the Invention
The invention relates to a new formulation of albumin and to uses of the
albumin
formulation.
Albumin is the most abundant protein in plasma. Albumin has been described and
characterized from a large number of mammals and birds. Albumin is believed to
have a role in
maintaining correct osmotic pressure and it also has a role in transport of
various compounds in
the blood stream. Albumin is a protein which is used to treat patients with
severe burns, shock
or blood loss. It is also used as an excipient for pharmacologically active
compounds, many of
which need to be stabilized for example to reduce the formation of soluble
aggregates and/or
insoluble aggregates of albumin. Furthermore, albumin is used to supplement
media used for
growing higher eukaryotic cells, including stem cells. Albumin fusion proteins
are a fusion of a
protein to albumin, or to a variant or fragment thereof, and may increase or
decrease the half-
life of the protein, for example increased in vivo half-life. Conjugation
partners, e.g proteins or
chemicals, can be conjugated to albumin to increase or decrease the half-life
of the conjugation
partner, for example increased in vivo half-life. At present albumin is
obtained from blood
products, such as serum, or produced recombinantly in microorganisms such as
yeast (e.g
W01996/037515, W02000/044772) or from transgenic plants or animals. Typically,
albumin is
purified from the production source in order to provide a product which is
sufficiently pure to
meet the user's needs and/or to achieve a high yield of product. In some
technical areas, such
as cell culture or pharmaceuticals, there is a desire for products to be
substantially free or
completely free of animal derived components.
Purified albumin in a final liquid form is relatively unstable (compared to
albumin in solid
form) and so in order to maximize its shelf life it is either lyophilized
and/or stabilizers added to
the final liquid formulation. However, lyophilization can add significantly to
the overall cost of
the preparation and can be inconvenient to the end user who would need to
resuspend the
lyophilized product if they need a liquid product. For the preferred liquid
product, stabilizers that
are commonly added to albumin are n-acetyl-tryptophan, octanoic acid
(octanoate, caprylate)
and/or polysorbate 80 (e.g Tween). The albumin of W02000/044772 is stabilized
by octanoic
1
CA 2838964 2018-11-21
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
acid. Arakawa & Kita (2000) discloses stabilizing effects of caprylate and
acetyltryptophanate
on heat-induced aggregation of bovine serum albumin (Biochimica of Biophysica
Acta 1479: 32-
36). Hosseini et al. (2002) discloses a study of the heat-treated human
albumin stabilization by
caprylate and acetyltryptophanate (Iranian Biomedical Journal 6(4): 135-140).
The present inventors have identified that octanoic acid, can be deleterious
to
mammalian cell culture particularly to stem cell culture. Furthermore,
polysorbate 80 (Tween )
can be deleterious to mammalian cell culture. What is required is a stable
liquid formulation of
albumin which is not deleterious to mammalian cell culture.
Summary of the Invention
The invention provides a liquid formulation of albumin with improved
stability, where
stability is shown, for example, as a reduced level of soluble aggregates of
albumin or insoluble
aggregates of albumin in the formulation. The invention also provides methods
using the
formulation and uses of the formulation, such as mammalian culture and
particularly stem cell
culture.
Brief Description of the Figures
Figure 1 shows the effect of pH and n-acetyl tryptophan concentration on the
stability of
albumin compositions (10 mg/mL), as determined by the time taken (seconds) for
the
absorbance (A350) to increase by 0.1 Absorbance Units (AU), a measure of
visible (insoluble)
aggregates.
Figure 2 shows the effect of pH and phosphate concentration on the stability
of albumin
compositions (10 mg/mL), as determined by the time taken (seconds) for the
absorbance
(A350) to increase by 0.1 AU.
Figure 3 shows the effect of pH and sodium concentration on the stability of
albumin
compositions (10 mg/mL), as determined by the time taken (seconds) for the
absorbance
(A350) to increase by 0.1 AU.
Figure 4 shows the effect of pH and sodium concentration (for a wide range of
sodium
concentrations) on the stability of albumin compositions (10 mg/mL), as
determined by the time
taken (seconds) for the absorbance (A350) to increase by 0.1 AU.
Figure 5 shows the effect of pH and sodium concentration on the stability of
albumin
compositions (50 mg/mL), as determined by the time taken (seconds) for the
absorbance
(A350) to increase by 0.1 AU.
2
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Figure 6 shows the effect of sodium concentration and albumin concentration on
the
stability of albumin compositions at pH 6.5, as determined by the time taken
(seconds) for the
absorbance (A350) to increase by 0.1 AU.
Figure 7 shows the relationship between sodium concentration and relative
monomer
content (%) for albumin compositions incubated at 40 C for 14 days.
Figure 8 shows the relationship between sodium concentration and relative
polymer
content (%) for albumin compositions incubated at 40 C for 14 days.
Figure 9 shows a fatty acid profile of an albumin formulation according to the
invention.
Figure 10 shows a metal ion profile, by ICP-OES, of an albumin formulation
according to
the invention.
Figure 11 shows the effect of sodium concentration and albumin concentration
on
albumin stability as determined by the remaining monomer content following
incubation at 40 C
for 4 weeks.
Figure 12 shows the effect of cation species and cation concentration on
albumin
stability as determined by the time taken (seconds) for the absorbance (A350)
to increase by
0.2 AU.
Figure 13 shows the effect of sodium ion concentration and anion species on
albumin
stability as determined by the time taken (seconds) for the absorbance (A350)
to increase by
0.1 AU.
Figure 14 shows the effect of sodium ion concentration and anion species on
albumin
stability as determined by the remaining monomer content following incubation
at 65 C for 2
hours.
Figure 15 shows the effect of sodium ion concentration in the presence of
different buffer
anions on albumin stability wherein the contribution of sodium from both NaCI
and the buffer is
included, as determined by the time taken (seconds) for the absorbance (A350)
to increase by
0.1 AU.
Figure 16 shows the effect of sodium ion concentration in the presence of no
buffering
ion or 50 mM citrate as a buffering ion on albumin stability where the
contribution of sodium ion
from the sodium citrate buffer is ignored, as determined by the time taken
(seconds) for the
absorbance (A350) to increase by 0.1 AU.
Figure 17 shows the effect of sodium ion concentration on the stability of
different
albumins and albumin variants as determined by the time taken (seconds) for
the absorbance
(A350) to increase by 0.1 AU.
3
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Figure 18 shows the effect of sodium ion concentration on the stability of
mouse serum
albumin as determined by the time taken (seconds) for the absorbance (A350) to
increase by
0.1 AU.
Figure 19 shows the effect of pH and sodium ion concentration on albumin
stability as
determined by the time taken (seconds) for the absorbance (A350) to increase
by 0.1 AU.
Figure 20 shows the effect of sodium ion concentration on albumin stability at
pH 5.0 as
determined by the time taken (seconds) for the absorbance (A350) to increase
by 0.1 AU.
Figure 21 shows the effect of sodium ion concentration on albumin stability at
pH 7.0, 7.5 and
8.0 as determined by the remaining monomer content following incubation at 65
C for 2 hours.
Detailed Description of the Invention
Definitions
The terms "cell culture medium", "culture medium" and "medium formulation"
refer
to a nutritive solution for culturing or growing cells.
A "serum-free" medium is a medium that contains no serum (e.g., fetal bovine
serum
(FBS), horse serum, goat serum, or any other animal-derived serum known to one
skilled in the
art).
The term "basal medium" refers to any medium which is capable of supporting
growth
of cells. The basal medium supplies standard inorganic salts, such as zinc,
iron, magnesium,
calcium and potassium, as well as trace elements, vitamins, an energy source,
a buffer system,
and essential amino acids. Suitable basal media include, but are not limited
to Alpha Minimal
Essential Medium (.alpha.MEM); Basal Medium Eagle (BME); Basal Medium Eagle
with Earle's
BSS; DME/F12; DMEM high Glucose with L-Glutamine; DMEM high glucose without L-
Glutamine; DMEM:FI2 1:1 with L-Glutamine; Dulbecco's Modified Eagle's Medium
(DMEM); F-
10; F-12; Glasgow's Minimal Essential Medium (G-MEM); G-MEM with L-glutamine;
Grace's
Complete Insect Medium; Grace's Insect Medium without FBS; Ham's F-10 with L-
Glutamine;
Ham's F-12 with L-Glutamine; IMDM with HEPES and L-Glutamine; IMDM with HEPES
and
without L-Glutamine; IPL-41 Insect Medium; Iscove's Modified Dulbecco's
Medium.; L-15
(Leibovitz) without L-Glutamine; L-15 (Leibovitz)(2X) without L-Glutamine or
Phenol Red;
McCoy's 5A Modified Medium; Medium 199; MEM Eagle without L-Glutamine or
Phenol Red
(2X); MEM Eagle-Earle's BSS with L-glutamine; MEM Eagle-Earle's BSS without L-
Glutamine;
MEM Eagle-Hanks BSS without L-Glutamine; Minimal Essential Medium (MEM);
Minimal
Essential Medium-alpha. (MEM-alpha); NCTC-109 with L-Glutamine; Richter's CM
Medium with
L-Glutamine; RPM! 1640; RPMI 1640 with L-Glutamine; RPM! 1640 without L-
Glutamine; RPMI
4
1640 with HEPES, L-Glutamine and/or Penicillin-Streptomycin; Schneider's
Insect Medium; or
any other media known to one skilled in the art. Preferred basal media for
stem cell culture
include MEF, DMEM, CTS, and DMEM/F-12.
The term "albumin" means a protein having the same and/or very similar
tertiary
structure as human serum albumin (HSA) or HSA domains and has similar
properties of HSA or
the relevant domains. Similar tertiary structures are for example the
structures of the albumins
from the species mentioned under parent albumin. Some of the major properties
of albumin are
i) its ability to regulate of plasma volume, ii) a long plasma half-life of
around 19 days 5 days,
iii) ligand-binding, e.g binding of endogenous molecules such as acidic,
lipophilic compounds
including bilirubin fatty acids, hemin and thyroxine (see also Table 1 of
Kragh-Hansen et a/,
2002, Biol. Pharm. Bull. 25, 695), iv) binding of small organic compounds with
acidic or
electronegative features e.g. drugs such as warfarin, diazepam, ibuprofen and
paclitaxel (see
also Table 1 of Kragh-Hansen et at, 2002, Biol. Pharm. Bull. 25, 695). Not all
of these
properties need to be fulfilled to in order to characterize a protein or
fragment as an albumin. If
a fragment, for example, does not comprise a domain responsible for binding of
certain ligands
or organic compounds the variant of such a fragment will not be expected to
have these
properties either. The term albumin includes variants, and/or derivatives such
as fusions and/or
conjugations of an albumin or of an albumin variant.
The term "variant' means a polypeptide derived from a parent albumin
comprising an
alteration, i.e., a substitution, insertion, and/or deletion, at one or more
(several) positions. A
substitution means a replacement of an amino acid occupying a position with a
different amino
acid; a deletion means removal of an amino acid occupying a position; and an
insertion means
adding 1-3 amino acids adjacent to an amino acid occupying a position. The
altered
polypeptide (variant) can be obtained through human intervention by
modification of the
polynucleotide sequence encoding the parental albumin. The variant albumin is
preferably at
least 70%, preferably at least 75%, more preferably at least 80%, more
preferably at least 85%,
even more preferably at least 90%, most preferably at least 95%, at least 96%,
at least 97%, at
least 98%, at least 99%, or 100% identical to SEQ ID NO: 2 and maintains at
least one of the
major properties of the parent albumin or a similar tertiary structure as HSA.
For purposes of the
present invention, the sequence identity between two amino acid sequences is
determined
using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. /Vol
Biol. 48: 443-
453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The
European Molecular Biology Open Software Suite, Rice et al, 2000, Trends Genet
16: 276-
277), preferably version 5Ø0 or later. The parameters used are gap open
penalty of 10, gap
5
CA 2838964 2018-11-21
extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62)
substitution
matrix. The output of Needle labeled "longest identity" (obtained using the
¨nobrief option) is
used as the percent identity and is calculated as follows: (Identical Residues
x 100)/(Length of
Alignment ¨ Total Number of Gaps in Alignment).
The variant may possess altered binding affinity to FcRn and/or an altered
rate of
transcytosis across endothelia, epithelia and/or mesothelia mono cell-layer
when compared to
the parent albumin. The variant polypeptide sequence is preferably one which
is not found in
nature. A variant includes a fragment, e.g comprising or consisting of at
least 100, 150, 200,
250, 300, 350, 450, 500, 550 contiguous amino acids of an albumin.
The term "wild-type" (WT) albumin means an albumin having the same amino acid
sequence as the albumins naturally found in an animal or in a human being. SEQ
ID NO: 2 is
an example of a wild-type albumin from Homo sapiens.
The term "parent" or "parent albumin" means an albumin to which an alteration
is made
to produce the albumin variants which may be used in the present invention.
The parent may
be a naturally occurring (wild-type) polypeptide or an allele thereof or a
variant thereof such as a
variant described in PCT/EP2010/066572 or a variant or derivative described in
PCT/EP2011/055577.
The term "fusion" means a genetic fusion of albumin (or a variant or fragment
thereof)
and a non-albumin protein. The non-albumin protein may be a therapeutic,
prophylactic, or
diagnostic protein. Examples of albumin fusions are provided in EP624195, WO
2001/079271,
WO 2003/059934, WO 2003/060071, W02011051489, PCT/EP11/055577 and EP11164955.
The term "conjugation" means an albumin (or a variant or fragment or fusion
thereof) to
which a non-albumin moiety is chemically conjugated. The non-albumin moiety
may be a
therapeutic, prophylactic, or diagnostic protein. Examples of albumin
conjugations are provided
in PCT/EP11/055577 and EP11164955.
The term -suspension culture" refers to cells in culture in which the majority
or all of
cells in culture are present in suspension, and the minority or none of the
cells in the culture
vessel are attached to the vessel surface or to another surface within the
vessel (adherent
cells). The "suspension culture" can have greater than about 50%, 60%, 65%,
75%, 85%, or
95% of the cells in suspension, not attached to a surface on or in the culture
vessel.
The term "adherent culture" refers to cells in culture in which the majority
or all of cells
in culture are present attached to the vessel surface or to another surface
within the vessel, and
6
CA 2838964 2018-11-21
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
the minority or none of the cells in the culture vessel are in suspension. The
"adherent culture"
can have greater than 50%, 60%, 65%, 75%, 85%, or 95% of the cells adherent.
As used herein, the term "mammal" includes any human or non-human mammal,
including but not limited to porcine, ovine, bovine, rodents, ungulates, pigs,
sheep, lambs, goats,
.. cattle, deer, mules, horses, primates (such as monkeys), dogs, cats, rats,
and mice.
The term "cell' includes any cell such as, but not limited to, any human or
non-human
mammalian cell as described herein. A cell may be a normal cell or an abnormal
cell (e.g.
transformed cells, established cells, or cells derived from diseased tissue
samples). The cell
may be a somatic cell such as a fibroblast or keratinocyte. Preferred cells
are stem cells such
as, but not limited to, embryonic stem cells, fetal stem cells, adult stem
cells and pluripotent
stem cells such as induced pluripotent stem cells. Particularly preferred
cells are human
embryonic stem cells, human fetal stem cells, human adult stem cells and human
pluripotent
stem cells such as induced human pluripotent stem cells.
A first aspect of the invention provides a composition comprising albumin, a
solvent, at
least 175 mM cations, having a pH from about 5.0 to about 9.0 and wherein the
composition
comprises equal to or less than 30 mM octanoate. An advantage of such a
composition is that
this formulation provides an albumin which is sufficiently stable to have a
useful shelf-life and is
not deleterious to the health of mammalian cells (e.g. it is not toxic) when
the composition is
used in mammalian cell culture.
It is preferred that the composition contains anions to balance the cations.
The solvent may be an inorganic solvent such as water or an inorganic buffer
such as a
phosphate buffer such as sodium phosphate, potassium phosphate, or an organic
buffer such
as sodium acetate or sodium citrate. The buffer may stabilize pH. Sodium
phosphate (e.g.
NaH2PO4) is a preferred pH buffer, such as pH 5.0, 5.5., 6.0, 6.5, 7.0, 7.5,
8Ø
The inventors have observed that octanoate is deleterious to mammalian cells
in cell
culture. Therefore, the composition comprises low levels of octanoate. For
example, it is
preferred that the composition comprises less than 30 mM octanoate, more
preferably less than
about 28, 26, 24, 22, 20, 18, 16, 15, 14, 12, 10, 8 mM octanoate, even more
preferably less
than about 6, 5,4, 3 mM octanoate, most preferably less than about 2, 1, 0.5,
0.4, 0.3, 0.2, 0.1,
0.01, or 0.001 mM octanoate. It is preferred that the composition is
substantially free of
octanoate. That is, it is preferred that the level of octanoate in the
composition is not sufficient
to cause a deleterious effect on cells during culture, for example mammalian
cells (particularly
7
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
stem cells such as human stem cells) in cell culture such as in vitro cell
culture. Most preferably
the composition is free of octanoate (0 mM octanaote).
Preferred parameters for fatty acids are provided below. The fatty acid
content is
preferably an average of multiple samples, for example 2, 3, 4 or 5 samples:
Fatty Acid Preferred range (mM)
06:0 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
C8:0 5 2.5 mM, more preferably 50.23 mM, most preferably 0 mM
09:0 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
C10:0 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
011:0 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
C12:0 5 0.5 mM, more preferably 5 0.05 mM, most preferably 0 mM
013:0 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
C14:0 5 10 mM, more preferably 1 5 mM, most preferably 0 mM
014:1 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
015:0 5 0.4 mM, more preferably 5 0.04 mM, most preferably 0 mM
015:1 5 0.1, more preferably 50.01 mM, most preferably 0 mM
016:0 5 34 mM, more preferably 5 3.38 mM, most preferably 0 mM
016:1n7 5 0.9 mM, more preferably 5 0.09 mM, most preferably 0 mM
016:2n4 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
016:3n4 5 0.5 mM, more preferably 5 0.05 mM, most preferably 0 mM
017:0 5 0.5 mM, more preferably 5 0.05 mM, most preferably 0 mM
017:1 5 0.1, more preferably 50.01 mM, most preferably 0 mM
018:0 5 20 mM, more preferably 5 2.05 mM, most preferably 0 mM
018:1n7 5 0.2 mM, more preferably 5 0.02 mM, most preferably 0 mM
018:1n9c 5 8 mM, more preferably 5 0.8 mM, most preferably 0 mM
018:1n9t 5 1.7 mM, more preferably 5 0.17 mM, most preferably 0 mM
018:2n6c 5 4.2 mM, more preferably 5 042 mM, most preferably 0 mM
018:2n6t 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
018:3n3 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
018:4n3 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
019:0 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
020:0 5 6 mM, more preferably 5 0.6 mM, most preferably 0 mM
020:1n9 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
8
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Fatty Acid Preferred range (mM)
C20:2n6 5 0.1 mM, more preferably 5Ø01 mM, most preferably 0
mM
020:3n3 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
020:3n6 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
C20:4n6 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
020:5n3 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
C22:0 5 5.7 mM, more preferably 5 0.57 mM, most preferably 0
mM
022:1n11 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
C22:1n9 5 0.1 mM, more preferably 50.01 mM, most preferably 0 mM
C22:2n6 <0.1 mM, more preferably 50.01 mM, most preferably 0 mM
It is also preferred that the overall fatty acid content of the composition is
less than or
equal to 20 mM, more preferably less than or equal to 15, 10, 5, 4, 3, 2 or 1
mM. It is more
preferred that the composition is substantially free of fatty acids, more
preferably free of fatty
acids.
A fatty acid profile and a metal ion profile of an albumin formulation
comprising 100 g.L-1
albumin, 5 1 mM octanoate, 250 mM Na + and having a pH of about 6.5 are
provided in Figures
9 and 10, respectively. These are particularly preferred profiles. The albumin
composition may
comply with one or both of the profiles of Fig 9 and Fig 10.
It is preferred that the cations are present from at least about 175 mM, for
example from
at least about 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475,
500, 525, 550, 575,
600, 650, 700, 750, 800, 850, 900, 950, 1000 mM. Preferred maximum cation
concentrations
include 1000, 950, 900, 850, 800, 750, 700, 650, 600, 575, 550, 525, 500, 475,
450, 425, 400,
375, 350, 325, 300, 275 and 250 mM. Preferred cation concentrations include
200 to 500 mM.
More preferred is a cation concentration of about 200 to 350 mM. Most
preferred is a cation
concentration of about 250 mM.
The pH of the composition may be between about 5.0 and about 9.0, for example
from
about 5.0, 5.25, 5.5, 5.75, 6.0, 6.25, 6.5, 6.75, 7.0, 7.25, 7.5, 7.75, 8.0,
8.25, or 8.5 to about 5.5,
5.75, 6.0, 6.25, 6.5, 6.75, 7.0, 7.25, 7.5, 7.75, 8.0, 8.25, 8.5, 8.75 or 9Ø
It is preferred that pH
is from about 5.0 to 8.0, such as from about 6.0 to about 8.0, more preferably
from about 6.0 to
about 7.0 or 6.0 to 6.5. Most preferred the pH is about 6.5.
The cations of the composition may be provided by any cation and may be
provided by
one or more (several) classes or species as described below. For example, the
cations may be
either mono or bivalent, monoatomic or polyatomic and may be provided by one
or more
9
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
(several) of an alkali metal (such as sodium, potassium), an alkaline earth
metal (such as
calcium, magnesium) or ammonium. It is preferred that the cations are provided
by sodium
and/or potassium and/or magnesium, most preferably sodium or magnesium.
Cations may be provided by a salt of an inorganic acid (e.g. a group 1 or 2
metal or
ammonium salt such as sodium chloride), a salt of a divalent acid (e.g. a
group 1 or group 2
metal or ammonium sulphate or phosphate such as sodium sulphate) or a salt of
an organic
acid (e.g. a group 1 or group 2 metal or ammonium salt of acetate or citrate
such as sodium
acetate).
Cations and anions used to stabilize the albumin may be provided by (i) salts
and/or (ii)
pH buffers such as described herein. Therefore, there may be more than one
(several) species
of cation or anion, such as 2, or 3 species. There may be more than one
(several) source of a
single cation, for example Na which may be provided by both a pH buffer (such
as sodium
phosphate) and a salt (such as NaCI).
Anions useful to the invention include inorganic anions such as phosphate, and
halides
such as chloride, and organic anions such as acetate and citrate. Anions may
be either mono or
bivalent, monoatomic or polyatomic. Preferred anions include sulphate, acetate
phosphate and
chloride, particularly chloride, sulphate and acetate.
Therefore, the composition may comprise one or more (several) of an alkali
metal
phosphate or chloride (such as sodium phosphate, potassium phosphate, sodium
chloride or
potassium chloride), an alkaline earth metal phosphate (such as calcium
phosphate,
magnesium phosphate, calcium chloride, magnesium chloride) or ammonium
phosphate or
ammonium chloride.
The composition may have an overall ionic strength of at least 175 mmol.L-1.
For
example, from about 175 to 1000 mmo11-1 such as from about 175, 200, 225, 250,
275, 300,
325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 650, 700, 750,
800, 850, 900, 950,
1000 mmol.L-1 to about 1000, 950, 900, 850, 800, 750, 700, 650, 600, 575, 550,
525, 500, 475,
450, 425, 400, 375, 350, 325, 300, 275, 250 mmol.L1. More preferred is an
overall ionic
strength of about 200 to 350 mmo1.111. Most preferred is an ionic strength of
about 250
mmo11-1.
The inventors have realized that the presence of stabilizers such as
detergents (e.g.
polysorbate 80 (Tween ')) can be deleterious to mammalian cells in cell
culture. Therefore, it is
preferred that the composition comprises less than 20 mg.L-1 detergent (e.g.
polysorbate 80),
preferably less than 15, 10, 5, 4, 3, 2, 1, 0.5, 0.1, 0.01, 0.001 mg1-1
detergent (e.g. polysorbate
80). Even more preferably, the composition is substantially free of detergent
(e.g. polysorbate
80). That is, it is preferred that the level of detergent (e.g polysorbate 80)
in the composition is
not sufficient to cause a deleterious effect on cells during culture, for
example mammalian cells
(particularly stem cells such as human stem cells) in cell culture such as in
vitro cell culture.
Most preferably the composition is free of detergent (e.g polysorbate 80).
Detergent (e.g
polysorbate 80) levels can be assayed by techniques known to the skilled
person for example,
but not limited to, the assay disclosed in WO 2004/099234.
For some cell media, it is preferred that the media is substantially free or
free of
tryptophan (e.g tryptophan-free RPM! 1640 as disclosed by Lee et a/(2002),
Immunology Vol
107(4): 452-460). An albumin composition may be added to a medium. Therefore,
in order to
maintain the tryptophan free character of a medium, an albumin composition
which has low
levels of amino acids (e.g N-acetyl tryptophan), is substantially free of
amino acids (e.g N-
acetyl tryptophan) or is free of amino acids (e.g N-acetyl tryptophan) is
useful. Therefore, it is
preferred that the albumin composition comprises less than 5 mM amino acids
(e.g. N-acetyl
tryptophan), preferably less than 4, 3, 2, 1, 0.5, 0.1, 0.01, 0.005, 0.001 mM
amino acids (e.g. N-
acetyl tryptophan). Even more preferably, the composition is substantially
free of amino acids
(e.g N-acetyl tryptophan). That is, it is preferred that the level of amino
acids (e.g N-acetyl
tryptophan) in the composition is not sufficient to cause a deleterious effect
on cells during
culture, for example mammalian cells (particularly stem cells such as human
stem cells) in cell
culture such as in vitro cell culture. Most preferably the composition is free
of amino acids (e.g
N-acetyl tryptophan).
It is even more preferred that the composition is substantially free of, or
completely free
of, octanoate, amino acids (e.g N-acetyl tryptophan) and detergent (e.g
polysorbate 80).
In order to identify whether or not there is a deleterious or toxic effect of
the albumin
formulation on cell culture, a test may be carried out by preparing a first
cell culture medium
containing the albumin formulation of the invention and preparing one or more
(several) control
cell culture media and monitoring their effect on cell lines. A control cell
culture medium is
identical to the first cell culture medium except that the albumin formulation
of the invention is
replaced with another albumin formulation, e.g an albumin formulation
stabilized with
octanoate, a detergent (e.g. polysorbate 80) and/or an amino acid (e.g n-
acetyl tryptophan).
The test media and controls may be used to cultivate one or more (several)
cell lines (e.g. a cell
line as described herein) and the effect of the albumin on the cells monitored
e.g by monitoring
cell growth, cell morphology and/or cell differentiation. It is preferred that
the test is carried out
over multiple passages of the cell line, e.g at least 2, 3, 4, 5, 6, 7, 8, 9
or 10 passages. Suitable
methods are known in the art. It is preferred that the albumin formulation of
the present
11
CA 2838964 2018-11-21
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
invention is less toxic or deleterious to cells than an albumin stabilized
with higher levels of
octanoate, detergent or amino acids. For example, a medium comprising the
albumin
composition of the invention may show at least a 2-, 5-, 10-, 100-, 1000-,
10000-, or 100000-fold
improvement over a control medium comprising another albumin formulation, e.g.
an albumin
formulation stabilized with octanoate, a detergent (e.g. polysorbate 80)
and/or an amino acid
(e.g. n-acetyl tryptophan). The 2, 5, 10, 100, 1000, 10000, or 100000-fold
improvement may
relate to viable cell numbers, correct or healthy cell morphology and/or to
the number or relative
number of differentiated cells, particularly cells showing differentiation to
a desired cell class or
type.
It is preferred that the stability of the albumin composition is higher than
that of
equivalent albumin in water or in 150 mM Na. One method to compare stability,
particularly
related to the formation of insoluble aggregates of albumin, is:
i) place an aliquot (e.g. 1 mL) of the albumin composition in a cuvette (e.g.
a polystyrene
cuvette, such as Sarstedt 10x4x45 mm);
ii) place the cuvette in a temperature controlled spectrophotometer that has
been pre-
equilibrated and controlled at a desired temperature, e.g. 65 C;
iii) Monitor / measure the absorbance of the composition at 350 nm, referenced
against
an empty cuvette over a desired time period (e.g. 2 hours) by taking a reading
at defined
intervals (e.g. every 18 seconds)
iv) Process the data by taking the first several (e.g. seven) data points,
average the data
point readings and subtract this data point from all data points in order to
provide base
absorbance values of around 0.
v) Determine and/or record the time taken for the processed absorbance values
to
increase by 0.1 AU (Absorbance Units) above this baseline.
It is preferred that stability analysis is performed in duplicate.
It is preferred that the stability of the albumin composition of the invention
is sufficiently
high so that the time taken for the measured absorbance to increase by 0.1 AU
above the
baseline (according to the above described test carried out at 65 C), compared
to a control
solution of albumin at the same concentration in a solvent such as 150 mM Na
or water and
measured under the same conditions is at least 10% better. It is more
preferred that the
stability is at least 20, 30, 40, 50, 60, 70, 80, 90 or 100% better.
An alternative or additional stability test, particularly for the formation of
soluble
aggregates of albumin, is to monitor the formation of soluble albumin polymer
by GP-H PLC over
time at a set temperature. One suitable stability study with measurement by GP
HPLC includes:
12
i) Placing 10mL sterilely (e.g by filtration through a sterile 0.22pm filter)
of each sample
to be investigated into sterile vials (e.g baked 10mL glass vials) which are
then stoppered (e.g
with a sterile butyl rubber seal and optionally over-sealed).
ii) A TO sample of ¨200pL is then taken and the vial is incubated at a
specified
temperature (e.g placed in a water bath that is set at a specified temperature
(e.g at 40 C)).
iii) Samples (-200pL) are then taken from each of the vials after certain time
points (e.g
14 days).
iv) injecting an aliquot (e.g. 25pL) of the albumin sample taken out of the
vial (at
<50mg/mL) onto a GP-HPLC column (e.g 7.8mm id x 300mm length TSK G3000SWXL
column, (Tosoh Bioscience), with a 6.0mm id x 40mm length TSK SW guard column
(Tosoh
Bioscience));
v) chromatographing the aliquot in a suitable buffer (e.g 25 mM sodium
phosphate, 100
mM sodium sulphate, 0.05% (w/v) sodium azide, pH 7.0) at a suitable speed (e.g
1mL/min)
vi) monitoring the chromatograph procedure e.g by UV detection at 280nm;
vii) quantifying one or more (several), or all, of monomer, dimer, trimer and
polymer
content of the aliquot as % (w/w) by identifying their respective peak area
relative to the total
peak area.
It is preferred that the test is carried out in triplicate.
Therefore, the invention also provides an albumin composition having a
stability as
defined in one or both of the above-mentioned tests, and a method for
producing an albumin
cornposition including one or both of the above-mentioned tests.
Albumin has been described and characterized from a large number of mammals
and
birds (e.g albumins listed in W02010/092135 (particularly Table 1) and
PCT/EP11/055577
(particularly page 9 and SEQ ID No: 2, 4-19 and 31).
The composition of the invention may comprise one or more (several) albumins.
Preferably the composition comprises an albumin selected from human albumin
(e.g
AAA98797 or P02768-1, SEQ ID NO: 2 (mature), SEQ ID NO: 3 (immature)), non-
human
primate albumin, (such as chimpanzee albumin (e.g predicted sequence
XP_517233.2 SEQ ID
NO: 4), gorilla albumin or macaque albumin (e.g. NP_001182578, SEQ ID NO: 5),
rodent
albumin (such as hamster albumin (e.g. A6YF56, SEQ ID NO: 6), guinea pig
albumin (e.g
Q6WDN9-1, SEQ ID NO: 7), mouse albumin (e.g AAH49971 or P07724-1 Version 3,
SEQ ID '
NO: 8, or the mature sequence SEQ ID NO: 19) and rat albumin (e.g AAH85359 or
P02770-1
Version 2, SEQ ID NO: 9))), bovine albumin (e.g. cow albumin P02769-1, SEQ ID
NO: 10),
13
CA 2838964 2018-11-21
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
equine albumin such as horse albumin (e.g. P35747-1, SEQ ID NO: 11) or donkey
albumin (e.g.
Q5XLE4-1, SEQ ID NO: 12), rabbit albumin (e.g. P49065-1 Version 2, SEQ ID NO:
13), goat
albumin (e.g. ACF10391, SEQ ID NO: 14), sheep albumin (e.g. P14639-1, SEQ ID
NO: 15), dog
albumin (e.g. P49822-1, SEQ ID NO: 16), chicken albumin (e.g. P19121-1 Version
2, SEQ ID
NO: 17) and pig albumin (e.g. P08835-1 Version 2, SEQ ID NO: 18). Mature forms
of albumin
are particularly preferred and the skilled person is able to identify mature
forms using publicly
available information such as protein databanks and/or by using signal peptide
recognition
software such as SignalP (e.g., SignalP (Nielsen et al., 1997, Protein
Engineering 10: 1-6)).
SignalP Version 4.0 is preferred (Petersen et al., 2011, Nature Methods (8):
785-786).
Human albumin as disclosed in SEQ ID NO: 2 or any naturally occurring allele
thereof, is
the preferred albumin of the albumin composition according to the invention.
SEQ ID NO: 2
may be encoded by the nucleotide sequence of SEQ ID NO: 1.
The albumin, particularly the human albumin, may be a variant, or a derivative
such as
fusion of conjugation of an albumin or of an albumin variant. It is preferred
that the albumin has
at least 70% identity to HSA (SEQ ID NO: 2), more preferably at least 72, 73,
75, 80, 85, 90, 95,
96, 97, 98, 99, 99.5 % identity to HSA. The albumin variant may have one or
more point
(several) mutations, e.g. K573P, K573Y, K573W, K500A compared to a parent
albumin such as
those provided in the sequence listing, particularly SEQ ID NO: 2 (mutations
are described in
relation to SEQ ID NO: 2 and the skilled person can identify equivalent
mutations in other
albumins by aligning an albumin sequence against SEQ ID NO: 2 using the EMBOSS
software
described herein). For an albumin having about 70 to 80 % identity to SEQ ID
NO: 2 (such as
mouse albumin e.g. SEQ ID NO: 19), it is more preferred that the cation is
present from at least
250 mM.
It is preferred that the albumin is present in the composition at a
concentration of from
about 1 g.L-1 to about 400 g.111. For example, the concentration may be from
about 1,5, 10, 25,
50, 75, 100, 125, 150, 175, 200, 225, 250, 275 g.L-1 to about 5, 10, 25, 50,
75, 100, 125, 150,
175, 200, 225, 250, 275, 300, 325, 350, 375 or 400 g.L-1. It is preferred that
the concentration of
albumin is from about 50 g.L-1 to about 200 g.L-1
Advantageously, the composition may comprise a recombinant albumin. That is,
the
albumin may be sourced from a recombinant organism such as a recombinant
microorganism,
recombinant plant or recombinant animal. Since some users prefer animal-free
ingredients, it is
more preferred that the albumin is sourced from a non-animal recombinant
source, such as a
recombinant microorganism or recombinant plant.
Preferred microorganisms include
prokaryotes and, more preferably, eukaryotes such as animals, plants, fungi or
yeasts, for
14
example, but not limited to, the following species in which albumins have been
successfully
expressed as recombinant proteins:
- fungi (including but not limited to Aspergillus (W006066595),
Nuyveromyces (Fleer 1991,
Bio/technology9, 968-975), Pichia (Kobayashi 1998 Therapeutic ApheresiS 2, 257-
262) and
Saccharomyces (Sleep 1990, Bio/lechnol0gy8, 42-46)), bacteria (Pandjaitab
2000, J. Allergy
Clln. immunol 105, 279-285)),
- animals (Barash 1993, Transgehic Research 2, 266-276)
- plants (including but not limited to potato and tobacco (Sijmons 1990,
Bionechnology8, 217
and Farran 2002, Transgenic Research 11, 337-346) and rice e.g. Oryza saliva)
- mammalian cells such as CHO and HEK.
The albumin of the invention is preferably produced recombinantly in a
suitable host
cell. Non-animal host cells are preferred. A preferred host is yeast,
preferably selected among
Pichie or Saccharomycacae, more preferred Saccharomyces cerevisiae.
A preferred composition comprises 50 to 250 g.L-1 albumin, 200 to 300 mM Nat,
20 to
30 mM phosphate, comprises less than 2 mM octanoate and has a pH between about
6.0 and
7Ø A particularly preferred composition comprises 50 to 150 g.L-1 albumin,
225 to 275 mM
Nat, 20 to 30 mM phosphate, comprises less than 1 mM octanoate and has a pH of
about 6.5.
Another aspect of the invention provides a composition comprising albumin, a
solvent,
at least 175 mM cations, having a pH from about 5.0 to about 8.0 or 9Ø An
advantage of such
a composition is that this formulation provides an albumin which is
sufficiently stable to have a
useful shelf-life and is not deleterious to the health of mammalian cells when
the composition is
used in mammalian cell culture. Preferred parameters for the solvent, cations,
ionic strength,
and pH are the same as those disclosed in relation to the first aspect of the
invention.
The albumin composition according to the invention may be provided in a
flexible
polymeric container, such as a bag. Suitable container volumes include from
about 50 mL to
about 10 000 mL, e.g 50 mL, 1000 mL, 5000 mL and 10 000 mL. It is preferred
that the
container comprises one or more (several) inlets or outlets to allow filling
of the container and/or
dispensing from the bag. The albumin composition may be sterilized, e.g prior
to or after being
filled in the container.
The production of recombinant albumin is known in the art and numerous hosts
such as
Escherichla co//(EP 73, 646), yeast has been reported in WO 00/44772, EP
0683233 A2, and
CA 2838964 2018-11-21
US 5,612,196, and Bacillus subtillis (Saunders at al, 1987, J. Bacteriol, 169,
2917-2925),
Aspergillus. Production of albumin has been demonstrated in transgenic plants
such as but not
limited to tobacco, rice, and maize and in transgenic animals such as but not
limited to chicken
and bovine
A second aspect of the invention provides a cell culture medium comprising a
composition as described herein and a basal medium. The cell culture medium
'may, for
example, be for the culture of mammalian cells such as human cells. The cell
culture medium
may, for example, be for the culture of stem cells or of gametes or of embryos
for example cell
culture for assisted reproductive technology (ART) purposes.
It is preferred that the cell culture medium is substantially free of animal-
derived
components. It is more preferred that the cell culture medium is free of
animal-derived
components. In this context, 'animal-derived component means a component which
has been
obtained from an animal. It does not include a component which is identical or
substantially
identical to an animal-derived component but which, instead of being obtained
from an animal,
is obtained as a recombinant component from a non-animal. A non-animal
includes a plant,
such as rice, a microorganism such as a yeast or bacterium.
Examples of cell culture media in which the albumin formulation may be used
include
those described in WO 2008/009641.
A cell culture medium comprising the albumin formulation of the first aspect
of the
invention may or may not comprise one or more (several) fatty acids, such as
provided by a
fatty acid supplement. Fatty acid supplements are commercially available, e.g
F7050 Fatty
Acid Supplement (Animal-component free, liquid, sterile-filtered, suitable for
cell culture)
available from Sigma-Aldrich.
A third aspect of the invention relates to use of an albumin formulation,
composition or
cell culture medium as described herein to culture cells, such as cells
described with reference
to the second aspect of the invention and or described below the fifth aspect
of the invention.
A fourth aspect of the invention relates to a method of culturing cells
comprising
incubating cells in a culture medium as described herein. The cells may be the
cells described
with reference to the second aspect of the invention and or described below
the fifth aspect of
the invention.
16
CA 2838964 2018-11-21
A fifth aspect of the invention relates to use of the albumin formulation of
the first aspect
of the invention in pharmaceutical products. Therefore, the invention also
provides a
pharmaceutical composition comprising the albumin formulation and an active
pharmaceutical
ingredient (API).
A sixth aspect of the invention relates to the use of a high cation
concentration to
stabilize albumin, e.g from at least 175 mM cations as described for the first
aspect of the
invention.
The compositions and media of the present invention may be used to culture a
variety of
cells. In one embodiment, the medium is used to culture eukaryotic cells such
as plant and/or
animal cells. The cells can be mammalian cells, fish cells, insect cells,
amphibian cells or avian
cells. The medium can be used to culture cells selected from the group
consisting of MK2.7
cells, PER-C6 cells, NSO, GS-NSO, CHO cells, HEK 293 cells, COS cells and
Sp2/0 cells.MK2.7
(ATCC Catalogue Number CRL 1909) is an anti-murine VCAM IgGI expressing
Hybridoma cell
line derived from the fusion of a rat splenocyte and a mouse Sp2/0 myeloma.
MK2.7 is a non-
adherent cell line that can be grown in serum-free media. Other types of cells
can be selected
from the group consisting of 5L8 hybridoma cells, Daudi cells, EL4 cells, HeLa
cells, HL-60
cells, K562 cells, Jurkat cells, THP-1 cells, Sp2/0 cells; and/or the
hybridoma cells listed in
Table 2, WO 2005/070120 or any other cell type disclosed herein or known to
one skilled in the
art.
Preferred cells include stem cells such as but not limited to, embryonic stem
cells, fetal
stem cells, adult stem cells and pleuripotent stem cells such as induced
pleuripotent stem cells.
Particularly preferred cells are human embryonic stem cells, human fetal stem
cells, human
adult stem cells and human pleuripotent stem cells such as induced human
pleuripotent stem
cells. The cell line may be derived from a blastocyst. The cell line may test
positive for one or
more (several) of the following cell markers: POU5F1 (OCT-4), SSEA-3, SSEA-4,
TRA1-60,
TRA1-81, ALPL, telomerase activity, and/or hES-CellectTM (CelJanis AB,
Gothenburg Sweden).
The cell line may test negative for cell marker ALPL and/or SSEA-1.
Particularly preferred cell
lines include SA121 and SA181 (Cellartis AB, Gothenburg, Sweden).
Additional mammalian cell types can include, but are not limited to, including
primary
epithelial cells (e.g keratinocytes, cervical epithelial cells, bronchial
epithelial cells, tracheal
epithelial cells, kidney epithelial cells and retinal epithelial cells) and
established cell lines and
their strains (e.g, 293 embryonic kidney cells, BHK cells, HeLa cervical
epithelial cells and
17
CA 2838964 2018-11-21
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
PER-06 retinal cells, MDBK (NBL-1) cells, 91 1 cells, CRFK cells, MDCK cells,
CHO cells,
BeWo cells, Chang cells, Detroit 562 cells, HeLa 229 cells, HeLa S3 cells, Hep-
2 cells, KB cells,
LS 180 cells, LS 174T cells, NCI-H-548 cells, RPMI2650 cells, SW-13 cells, T24
cells, WI-28
VA13, 2RA cells, WISH cells, BS-C-I cells, LLC-PK<sub>2</sub> cells, Clone M-3
cells, 1-10 cells,
RAG cells, TCMK-1 cells, Y-1 cells, LLC-PK<sub>1</sub> cells, PK(15) cells, GH.1
cells, GH3 cells, L2
cells, LLC-RC 256 cells, MH<sub>IC1</sub> cells, XC cells, MDOK cells, VSW cells,
and TH-I, B1 cells,
or derivatives thereof), fibroblast cells from any tissue or organ (including
but not limited to
heart, liver, kidney, colon, intestines, esophagus, stomach, neural tissue
(brain, spinal cord),
lung, vascular tissue (artery, vein, capillary), lymphoid tissue (lymph gland,
adenoid, tonsil, bone
marrow, and blood), spleen, and fibroblast and fibroblast-like cell lines
(e.g., CHO cells, TRG-2
cells, IMR-33 cells, Don cells, GHK-2 1 cells, citrullinemia cells, Dempsey
cells, Detroit 551
cells, Detroit 510 cells, Detroit 525 cells, Detroit 529 cells, Detroit 532
cells, Detroit 539 cells,
Detroit 548 cells, Detroit 573 cells, HEL 299 cells, IMR-90 cells, MRC-5
cells, WI-38 cells, WI-26
cells, MiCl<sub>1</sub> cells, CHO cells, CV-1 cells, COS-1 cells, COS-3 cells, COS-
7 cells, Vero
cells, DBS-FrhL-2 cells, BALB/313 cells, F9 cells, SV-12 cells, M-MSV-BALB/3T3
cells, K-BALB
cells, BLO-11 cells, NOR-10 cells, C3H/I0T1/2 cells, HSDM<sub>IC3</sub> cells,
KLN205 cells, McCoy
cells, Mouse L cells, Strain 2071 (Mouse L) cells, L-M strain (Mouse L) cells,
L-MTK (Mouse L)
cells, NCTC clones 2472 and 2555, SCC-PSA1 cells, Swiss/3T3 cells, Indian
muntjac cells,
SIRC cells, CII cells, and Jensen cells, or derivatives thereof).
Cells include cancer cells such, but not limited to, the following cancer cell
lines: human
myeloma (e.g., KMM-1, KMS-11, KMS-12-PE, KMS-12-BM, KMS-18, KMS-20, KMS-21-PE,
U266, RPMI8226); human breast cancer (e.g., KPL-1, KPL-4, MDA-MB-231, MCF-7,
KPL-3C,
T47D, SkBr3, HS578T, M0A4355, Hs 606 (CRL-7368), Hs 605.1 (CRL-7365) HS 742.T
(CRL-
7482), BT-474, HBL-100, HCC202, HCC1419, HCC1954, MCF7, MDA-361 MDA-436, MDA-
453, SK-BR-3, ZR-75-30, UACC-732, UACC-812, UACC-893, UACC-3133, MX-1 and EFM-
192A); ductal (breast) carcinoma (e.g., HS 57HT (HTB-126), HCC1008 (CRL-2320),
HCC1954
(CRL-2338; HCC38 (CRL-2314), HCC1143 (CRL-2321), HCC1187 (CRL-2322), HCC1295
(CRL-2324), HCC1599 (CRL-2331), HCC1937 (CRL-2336), HCC2157 (CRL-2340),
HCC2218
(CRL-2343), Hs574.T (CRL-7345), Hs 742.T (CRL-7482); skin cancer (e.g., COLO
829 (CRL-
1974), TE 354.T (CRL-7762), Hs 925.1 (CIU-7677)); human prostate cancer (e.g.,
MDA PCa 2a
and MDA PCa 2b); bone cancer (e.g., Hs 919.T (CRL-7672), Hs 821.1 (CRL-7554),
Hs 820.1
(CRL-7552)y HS 704.T (CRL-7444), HS 707(A).T (CRL-7448), HS 735.T (CRL-7471),
HS 860.1
(CRL-7595)y HS 888.T.(CRL-7622); HS 889.1 (CRL-7626); HS 890.1 (CRL-7628), Hs
709.1
(CRL-7453)); human lymphoma (e.g., K562); human cervical carcinoma (e.g.,
HeLA); lung
18
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
carcinoma cell lines (e.g., H125, H522, H1299, NCI-H2126 (ATCC CCL-256), NCI-
H1672
(ATCC CRL-5886), NCI-2171 (CRL-5929); NCI-H2195 (CRL05931); lung
adenocarcinoma (e.g.,
NCI-H1395 (CRL-5856), NCI-H1437 (CRL-5872), NCI-H2009 (CRL-5911), NCI-H2122
(CRL-
5985), NCI-H2087 (CRL-5922); metastatic lung cancer (e.g., bone) (e.g., NCI-
H209 (HTB-172);
colon carcinoma cell lines (e.g., LN235, DLD2, Colon A, LIM2537, LIM1215,
LIM1863, LIM1899,
LIM2405, LIM2412, SK-001 (ATCC HTB-77), H129 (ATCC HTB38), LoVo (ATCC CCL-
229),
SW1222 (ATCC HB-11028), and SW480 (ATCC CCL-228); ovarian cancer (e.g., OVCAR-
3
(ATCC HTB-161) and SKOV-3 (ATCC HTB-77); mesothelioma (e.g., NCI-h2052 (CRL-
5915);
neuroendocrine carcinoma (e.g., HCI-H1770 (e.g., CRL-5893); gastric cancer
(e.g., LIM1839);
glioma (e.g., T98, U251, LN235); head and neck squamous cell carcinoma cell
lines (e.g.,
SCC4, SCC9 and SCC25); medulloblastoma (e.g., Daoy, D283 Med and D341 Med);
testicular
non-seminoma (e.g., TERA1); prostate cancer (e.g., 178-2BMA, Du145, LNCaP, and
PC-3).
Other cancer cell lines are well known in the art.
The media disclosed herein can be used to culture cells in suspension or
adherent cells.
The media of the present invention are suitable for adherent, monolayer or
suspension culture,
transfection, and/or cultivation of cells, and for expression of proteins or
antibodies in cells in
monolayer or suspension culture.
Cell culture can be performed using various culture devices, for example, a
fermenter
type tank culture device, an air lift type culture device, a culture flask
type culture device, a
spinner flask type culture device, a microcarrier type culture device, a
fluidized bed type culture
device, a hollow fiber type culture device, a roller bottle type culture
device, a packed bed type
culture device or any other suitable device known to one skilled in the art.
The present invention is further described by the following examples that
should not be
construed as limiting the scope of the invention.
Examples
Example 1: Effect of n-acetyl-tryptophan, phosphate concentration and sodium
concentration on the stability of albumin.
Aim: Previous work indicated that monitoring the formation of insoluble
aggregates at 65 C,
through an increase in absorption at 350 nm, is a valid method for screening
of the effect of
different formulation (composition) parameters on the stability of albumin.
Since octanoate and
polysorbate 80 appear to be detrimental to stem cell growth, it is preferred
that an albumin
formulation is substantially free of these components. This Example analyzes
the effect of pH,
19
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
sodium ion and buffer concentration on the stability of albumin. A common
stabilizer for albumin
is n-acetyl-tryptophan, therefore it is included in this Example as a test
constituent.
Method: Albumin at 100 mg/mL in 145 mM NaCI (albumin batch 1401) was diluted
to 10 mg/mL
according to Table 3. The buffers used for dilution are shown in Tables 1 and
2.
Na Molarity Tryptophan
Molarity
Table 1 rHSA Conc (g/L)
(mM) (mM)
rHSA solution (1401) 100 154
5 M NaCI 5000
Tryptophan 501 500
Table 2
Buffer Stock Solution Phosphate (mM) Na (mM)
0.5 M Phosphate pH 4 502 500
0.5 M Phosphate pH 5 500 518
0.5 M Phosphate pH 6 500 634
0.5 M Phosphate pH 7 500 851
0.5 M Phosphate pH 8 500 970
0.5 M Phosphate pH 9 500 992
CA 02838964 2013-12-09
WO 2013/006675
PCT/US2012/045505
Table 3 Stock Volumes to Add (mL)
Sodium Actual
Sample rHSA NaCl Tryptophan Water
Phosphate pH
pH 4, 145 mM Sodium, 50
0.500 0.498 0.080 0.000 3.922 4.06
mM Phosphate
pH 5, 145 mM Sodium, 50
0.500 0.500 0.078 0.000 3.922 5.03
mM Phosphate
pH 6, 145 mM Sodium, 50
0.500 0.500 0.066 0.000 3.934 6.03
mM Phosphate
pH 7, 145 mM Sodium, 50
0.500 0.500 0.045 0.000 3.956 7.04
mM Phosphate
pH 8, 145 mM Sodium, 50
0.500 0.500 0.033 0.000 3.967 7.90
mM Phosphate
pH 9, 145 mM Sodium, 50
0.500 0.500 0.030 0.000 3.970 8.84
mM Phosphate
pH 5.5, 145 mM Sodium,
0.500 0.500 0.078 0.000 3.922 5.49
50 mM Phosphate
pH 6, 145 mM Sodium, 50
0.500 0.500 0.066 0.000 3.934 5.97
mM Phosphate
pH 6.5, 145 mM Sodium,
0.500 0.500 0.066 0.000 3.934 6.48
50 mM Phosphate
pH 4, 145 mM Sodium, 50
mM Phosphate, 5 mM 0.500 0.498 0.075 0.050 3.877
3.98
Tryptophan
pH 5, 145 mM Sodium, 50
mM Phosphate, 5 mM 0.500 0.500 0.073 0.050 3.877
5.00
Tryptophan
pH 6, 145 mM Sodium, 50
mM Phosphate, 5 mM 0.500 0.500 0.061 0.050 3.889
6.00
Tryptophan
pH 7, 145 mM Sodium, 50
mM Phosphate, 5 mM 0.500 0.500 0.039 0.050 3.911
7.08
Tryptophan
21
CA 02838964 2013-12-09
WO 2013/006675
PCT/US2012/045505
Table 3 Stock Volumes to Add (mL)
Sodium Actual
Sample rHSA NaCl Tryptophan Water
Phosphate pH
pH 8, 145 mM Sodium, 50
mM Phosphate, 5 mM 0.500 0.500 0.028 0.050 3.922
8.01
Tryptophan
pH 9, 145 mM Sodium, 50
mM Phosphate, 5 mM 0.500 0.500 0.025 0.050 3.925
9.09
Tryptophan
pH 4, 145 mM Sodium, 50
mM Phosphate, 2 mM 0.500 0.498 0.078 0.020 3.904 4.06
Tryptophan
pH 5, 145 mM Sodium, 50
mM Phosphate, 2 mM 0.500 0.500 0.076 0.020 3.904 5.01
Tryptophan
pH 6, 145 mM Sodium, 50
mM Phosphate, 2 mM 0.500 0.500 0.064 0.020 3.916 6.06
Tryptophan
pH 7, 145 mM Sodium, 50
mM Phosphate, 2 mM 0.500 0.500 0.042 0.020 3.938 7.01
Tryptophan
pH 8, 145 mM Sodium, 50
mM Phosphate, 2 mM 0.500 0.500 0.031 0.020 3.949 7.99
Tryptophan
pH 9, 145 mM Sodium, 50
mM Phosphate, 2 mM 0.500 0.500 0.028 0.020 3.952 9.03
Tryptophan
pH 4, 50 mM Sodium, 25
0.500 0.249 0.010 0.000 4.241 4.03
mM Phosphate
pH 5, 50 mM Sodium, 25
0.500 0.250 0.009 0.000 4.241 5.02
mM Phosphate
pH 6, 50 mM Sodium, 25
0.500 0.250 0.003 0.000 4.247 5.82
mM Phosphate
22
CA 02838964 2013-12-09
WO 2013/006675
PCT/US2012/045505
Table 3 Stock Volumes to Add (mL)
Sodium Actual
Sample rHSA NaCl Tryptophan Water
Phosphate pH
pH 7, 50 mM Sodium, 25
0.500 0.250 0.000 0.000 4.250
7.05
mM Phosphate
pH 8, 50 mM Sodium, 25
0.500 0.250 0.000 0.000 4.250
7.97
mM Phosphate
pH 9, 50 mM Sodium, 25
0.500 0.250 0.000 0.000 4.250
8.88
mM Phosphate
pH 5.5, 50 mM Sodium,
0.500 0.250 0.009 0.000 4.241
5.48
25 mM Phosphate
pH 6, 50 mM Sodium, 25
0.500 0.250 0.003 0.000 4.247
6.18
mM Phosphate
pH 6.5, 50 mM Sodium,
0.500 0.250 0.003 0.000 4.247
6.60
25 mM Phosphate
pH 4, 300 mM Sodium, 25
0.500 0.249 0.260 0.000 3.991
4.03
mM Phosphate
pH 5, 300 mM Sodium, 25
0.500 0.250 0.259 0.000 3.991
5.06
mM Phosphate
pH 6, 300 mM Sodium, 25
0.500 0.250 0.253 0.000 3.997
6.06
mM Phosphate
pH 7, 300 mM Sodium, 25
0.500 0.250 0.242 0.000 4.008
6.99
mM Phosphate
pH 8, 300 mM Sodium, 25
0.500 0.250 0.236 0.000 4.014
8.02
mM Phosphate
pH 9, 300 mM Sodium, 25
0.500 0.250 0.235 0.000 4.015
9.00
mM Phosphate
pH 5.5, 300 mM Sodium,
0.500 0.250 0.259 0.000 3.991
5.61
25 mM Phosphate
pH 6, 300 mM Sodium, 25
0.500 0.250 0.253 0.000 3.997
6.19
mM Phosphate
pH 6.5, 300 mM Sodium,
0.500 0.250 0.253 0.000 3.997
6.61
25 mM Phosphate
23
CA 02838964 2013-12-09
WO 2013/006675
PCT/US2012/045505
Table 3 Stock Volumes to Add (mL)
Sodium Actual
Sample rHSA NaCl Tryptophan Water
Phosphate pH
pH 4, 145 mM Sodium, 0
0.500 0.000 0.130 0.000 4.370
4.05
mM Phosphate
pH 5, 145 mM Sodium, 0
0.500 0.000 0.130 0.000 4.370
5.02
mM Phosphate
pH 6, 145 mM Sodium, 0
0.500 0.000 0.130 0.000 4.370
5.99
mM Phosphate
pH 7, 145 mM Sodium, 0
0.500 0.000 0.130 0.000 4.370
6.97
mM Phosphate
pH 8, 145 mM Sodium, 0
0.500 0.000 0.130 0.000 4.370
8.02
mM Phosphate
pH 9, 145 mM Sodium, 0
0.500 0.000 0.130 0.000 4.370
9.02
mM Phosphate
pH 5.5, 145 mM Sodium,
0.500 0.000 0.130 0.000 4.370
5.47
0 mM Phosphate
pH 6, 145 mM Sodium, 0
0.500 0.000 0.130 0.000 4.370
6.30
mM Phosphate
pH 6.5, 145 mM Sodium,
0.500 0.000 0.130 0.000 4.370
6.65
0 mM Phosphate
pH 4, 145 mM Sodium,
0.500 0.996 0.030 0.000 3.474
3.98
100 mM Phosphate
pH 5, 145 mM Sodium,
0.500 1.000 0.026 0.000 3.474
4.91
100 mM Phosphate
pH 6, 145 mM Sodium,
0.500 0.999 0.003 0.000 3.498
5.98
100 mM Phosphate
pH 7, 145 mM Sodium,
0.500 1.000 -0.041 0.000 3.541
7.03
100 mM Phosphate
pH 8, 145 mM Sodium,
0.500 1.000 -0.064 0.000 3.564
8.10
100 mM Phosphate
pH 9, 145 mM Sodium,
0.500 0.999 -0.069 0.000 3.569
9.03
100 mM Phosphate
24
CA 02838964 2013-12-09
WO 2013/006675
PCT/US2012/045505
Table 3 Stock Volumes to Add (mL)
Sodium Actual
Sample rHSA NaCl Tryptophan Water
Phosphate pH
pH 5.5, 145 mM Sodium,
0.500 0.999 0.026 0.000
3.474 5.58
100 mM Phosphate
pH 6, 145 mM Sodium,
0.500 0.999 0.003 0.000
3.498 6.22
100 mM Phosphate
pH 6.5, 145 mM Sodium,
0.500 0.999 0.003 0.000
3.498 6.60
100 mM Phosphate
Once diluted the samples were adjusted to their target pH with 1 M HCI, the
volume of
which was insignificant and does not alter the final albumin or constituent
concentrations. An
aliquot (1 mL) of the resulting solution was then placed in a polystyrene
cuvette (Sarstedt
10x4x45 mm). The cuvette was then placed into a temperature controlled
spectrophotometer
that had been pre-equilibrated and controlled at 65 C. The absorbance at 350
nm, referenced
against an empty cuvette, was then monitored over a 2 hour period with a
reading being taken
every 18 seconds. The data were processed by taking the first 7 data points,
averaging them
(calculating the mean) and then subtracting this from all data points in order
to give base
absorbance values of around 0. The time taken for this absorbance to then
increase by 0.1 AU
(Absorbance Units) above this baseline was then recorded for that particular
formulation
sample. Each formulation sample was performed in duplicate and the time for
the absorbance
to increase by 0.1 AU for each replicate averaged.
Results: The processed data with the time for each sample to increase by 0.1
AU, were plotted
for time for absorbance increase against pH for each of the formulation
constituents tested; n-
acetyl-tryptophan, phosphate concentration and sodium concentration. Values
above 7200 sec
were extrapolated. The data are presented in Figs 1 (pH and n-acetyl
tryptophan), 2 (pH and
phosphate) and 3 (pH and sodium).
Conclusions:
= For all the data, except for 50 mM sodium, the optimum pH was between pH
6 and 7.
For 50 mM sodium, although insoluble aggregates were not forming, it is
possible that high
levels of soluble oligomers were being generated and these were not coalescing
to form
insoluble aggregates. Soluble aggregates can be identified by GP-HPLC.
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
= For the phosphate buffer concentration, there was no significant
difference between 50
and 100 mM. However, 0 mM phosphate did appear to be slightly more stable
between pH 6 to
8. Although using no phosphate would be best in terms of stability, the use of
a buffer aids pH
control, for example because it reduces or eliminates the requirement to pH-
adjust an albumin
prior to formulation.
= Increasing sodium levels had a significant effect on stability with a
large increase in
stability between 145 and 300 mM sodium.
Example 2: Effect of increasing sodium concentration on albumin stability.
Aim: Example 1 indicated that increased levels of sodium had a beneficial
effect on albumin
stability. To investigate this further, increasing concentrations of sodium
over a wider range
than in Example 1 at the optimum pH range were investigated.
Method: Albumin at 100 mg/mL in 145 mM NaCI (albumin batch 1401) was diluted
to 10 mg/mL
according to the Table 6. The buffers used for dilution are shown in Tables 4
and 5.
Table 4 rHSA Conc (g/L) Na Molarity (mM) Tryptophan
Molarity
(mM)
rHSA solution (1401) 100 154
5 M NaCI 5000
Tryptophan 501 500
Table 5
Buffer Stock Solution Phosphate (mM) Na (mM)
0.5 M Phosphate pH 4 502 500
0.5 M Phosphate pH 5 500 518
0.5 M Phosphate pH 6 500 634
0.5 M Phosphate pH 7 500 851
0.5 M Phosphate pH 8 500 970
0.5 M Phosphate pH 9 500 992
26
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Table 6: Stock Volumes to Add (mL)
Sample
rHSA Sodium Phosphate NaCI Water
pH 6.5, 50 mM Sodium, 25 mM Phosphate 0.500 0.250 0.003
4.247
pH 6.5, 100 mM Sodium, 25 mM Phosphate 0.500 0.250 0.053
4.197
pH 6.5, 150 mM Sodium, 25 mM Phosphate 0.500 0.250 0.103
4.147
pH 6.5, 200 mM Sodium, 25 mM Phosphate 0.500 0.250 0.153
4.097
pH 6.5, 250 mM Sodium, 25 mM Phosphate 0.500 0.250 0.203
4.047
pH 6.5, 400 mM Sodium, 25 mM Phosphate 0.500 0.250 0.353
3.897
pH 6.0, 50 mM Sodium, 25 mM Phosphate 0.500 0.250 0.003
4.247
pH 6.0, 100 mM Sodium, 25 mM Phosphate 0.500 0.250 0.053
4.197
pH 6.0, 150 mM Sodium, 25 mM Phosphate 0.500 0.250 0.103
4.147
pH 6.0, 200 mM Sodium, 25 mM Phosphate 0.500 0.250 0.153
4.097
pH 6.0, 250 mM Sodium, 25 mM Phosphate 0.500 0.250 0.203
4.047
pH 6.0, 400 mM Sodium, 25 mM Phosphate 0.500 0.250 0.353
3.897
pH 7.0, 50 mM Sodium, 25 mM Phosphate 0.500 0.250 0.000
4.250
pH 7.0, 100 mM Sodium, 25 mM Phosphate 0.500 0.250 0.042
4.208
pH 7.0, 150 mM Sodium, 25 mM Phosphate 0.500 0.250 0.092
4.158
pH 7.0, 200 mM Sodium, 25 mM Phosphate 0.500 0.250 0.142
4.108
pH 7.0, 250 mM Sodium, 25 mM Phosphate 0.500 0.250 0.192
4.058
pH 7.0, 400 mM Sodium, 25 mM Phosphate 0.500 0.250 0.342
3.908
The dilution was performed by first mixing the albumin and buffer as a bulk
and then
adjusting it to the correct pH by the addition of 1 M HCI. This was then
divided and water and 5
M NaCI added as appropriate. This ensured that all samples were at exactly the
same pH. An
aliquot (1 mL) of the resulting solution was then placed in a polystyrene
cuvette (Sarstedt
10x4x45 mm). The cuvette was then placed into a temperature controlled
spectrophotometer
that had been pre-equilibrated and controlled at 65 C. The absorbance at 350
nm, referenced
against an empty cuvette, was then monitored over a 2 hour period with a
reading being taken
every 18 seconds. The data were processed by taking the first 7 data points,
averaging them
(calculating the mean) and then subtracting this from all data points in order
to give base
absorbance values of around 0. The time taken for this absorbance to then
increase by 0.1 AU
above this baseline was then recorded for that particular formulation sample.
Each formulation
27
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
sample was performed in duplicate and the time for the absorbance to increase
by 0.1 AU for
each replicate averaged.
Results: The processed data with the time for each sample to increase by 0.1
AU, were plotted
for time for absorbance increase against Na concentration for each pH. Values
above 7200 sec
were extrapolated. The data are shown in Fig. 4.
Conclusion:
= Consistent with Example 1, increasing levels of sodium increased albumin
stability. This
was particularly the case around 200 mM where there was a sudden increase in
stability. This
was the case for all pHs, although it was less obvious at pH 6 since even at
<200 mM
increasing salt was still having a beneficial effect. The fact that the
increase was around 200
mM maybe the reason that it has not been observed previously, since most other
albumin
formulations are 150 mM or lower in order to keep them approximately
physiological. For an
.. albumin used in cell culture media, this should not be an issue as the
albumin will be diluted
down into the media and the overall salt concentration of the media will be
suitable for cell
culture.
= pH 6 was slightly better than pH 6.5, both being significantly better
than pH 7.
Example 3: Effect of sodium concentration on the stability of different
concentrations of
albumin.
Aim: Example 2 shows that sodium concentration is important to stability of
albumin. Example
2 was done at an albumin concentration of 10 mg/mL. In order to confirm that
this effect is also
true at higher concentrations the effect of sodium at higher albumin
concentrations was
investigated.
Method: Albumin at 100 mg/mL in 145 mM NaCI (albumin batch 1401) was diluted
to 50 or 90
mg/mL according to Table 9. The buffers used for dilution are shown in Tables
7 and 8.
Table 7 rHSA Conc (g/L) Na Molarity (mM) Tryptophan Molarity
(mM)
,
rHSA solution (1401) 100 154 -
,
5 M NaCI - 5000 -
_
Tryptophan - 501 500
28
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Table 8
Buffer Stock Solution Phosphate (mM) Na (mM)
0.5 M Phosphate pH 4 502 500
0.5 M Phosphate pH 5 500 518
0.5 M Phosphate pH 6 500 634
0.5 M Phosphate pH 7 500 851
--,
0.5 M Phosphate pH 8 500 970
0.5 M Phosphate pH 9 500 992
Table
Sample Stock Volumes to Add (mL)
9
rHSA
conc Sodium
Sample rHSA NaCI H20
(mg/mL) Phosphate
pH 6.5, 100 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.000 1.350
pH 6.5, 150 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.025 1.325
pH 6.5, 200 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.055 1.295
pH 6.5, 250 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.085 1.265
pH 6.5, 300 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.115 1.235
pH 6.5, 400 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.175 1.175
pH 6.0, 200 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.055 1.295
pH 6.0, 250 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.085 1.265
pH 6.0, 300 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.115 1.235
pH 7.0, 200 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.048 1.302
pH 7.0, 250 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.078 1.272
pH 7.0, 300 mM Sodium, 25 mM Phosphate 50 1.500 0.150 0.108 1.242
pH 6.5, 200 mM Sodium, 25 mM Phosphate 90 2.700 0.150 0.018 0.132
pH 6.5, 250 mM Sodium, 25 mM Phosphate 90 2.700 0.150 0.048 0.102
pH 6.5, 300 mM Sodium, 25 mM Phosphate 90 2.700 0.150 0.078 0.072
pH 6.5, 300 mM Sodium, 25 mM Phosphate 90 2.700 0.150 0.078 0.072
pH 6.5, 350 mM Sodium, 25 mM Phosphate 90 2.700 0.150 0.108 0.042
pH 6.5, 400 mM Sodium, 25 mM Phosphate 90 2.700 0.150 0.138 0.012
29
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
The dilution was performed by first mixing the albumin and buffer as a bulk
and then
adjusting it to the correct pH by the addition of 1 M HCI. This was then
divided and water and 5
M NaCI added as appropriate. This ensured that all samples were at exactly the
same pH.
An aliquot (1 mL) of the resulting solution was then placed in a polystyrene
cuvette
(Sarstedt 10x4x45 mm). The cuvette was then placed into a temperature
controlled
spectrophotometer that had been pre-equilibrated and controlled at 65 C. The
absorbance at
350 nm, referenced against an empty cuvette, was then monitored over a 2 hour
period with a
reading being taken every 18 seconds. The data were processed by taking the
first 7 data
points, averaging them (calculating the mean) and then subtracting this from
all data points in
order to give base absorbance values of around 0. The time taken for this
absorbance to then
increase by 0.1 AU above this baseline was then recorded for that particular
formulation
sample. Each formulation sample was performed in duplicate and the time for
the absorbance
to increase by 0.1 AU for each replicate averaged.
Results: The processed data with the time for each sample to increase by 0.1
AU were plotted
for time for absorbance increase against Na concentration for each pH (6.0,
6.5 and 7.0) at 50
mg/mL albumin and then for 3 different albumin concentrations (10, 50 and 90
mg/mL) at pH
6.5. The data are shown in Figs 5 and 6.
Conclusions:
= At 50 mg/mL albumin the trend of increasing sodium concentration
improving albumin
stability was confirmed at all 3 pHs. In this instance pH 6.5 was the best.
= At pH 6.5, the trend of increased sodium improving stability was again
confirmed at all
albumin concentrations. The trend was not as pronounced at 90 g/L, but it was
still the case
that sodium concentrations above 200 mM significantly improved the albumin
stability.
Example 4: Effect of sodium concentration on the production of soluble
aggregates in
albumin.
Aim: Examples 1 to 3 show, using the formulation screening assay that measures
insoluble
aggregates, that increasing sodium concentrations improved albumin stability.
In order to look
at soluble aggregates (albumin polymer) GP-HPLC needs to be used as the
measurement tool
with polymer formation monitored in an accelerated stability trial at 40 C
over a 2 week period.
The tests were carried out at pH 6.5 because this was shown, by Examples 1 to
3, to be a
preferred pH. A control of albumin in previous formulation conditions (pH 8.6,
150 mM Na) was
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
also used to confirm that a new formulation would be significantly beneficial.
The actual
albumin concentration was 90 mg/mL instead of the anticipated 100 mg/mL as
this was the
highest that could be used allowing for dilution into the various
formulations. However, it is
thought that observed trends at this slightly lower concentration will be the
same at higher
albumin concentrations.
Method: Albumin at 100 mg/mL in 145 mM NaCI (albumin batch 1401) was diluted
to 90 mg/mL
according to Table 12. The buffers used for dilution are shown in Tables 10
and 11.
Table 10 rHSA Conc (g/L) Na Molarity (mM)
rHSA solution (1401) 100 154
5 M NaCI 5000
Table 11
Buffer Stock Make up NaH2PO4.2H20 27% NaOH Phosphate
Na (mM)
Solution Vol (mL) (g) (mL)* (mM)
0.5 M Phosphate
pH 6 250 19.51 3.8 500 634
*27% w/w NaOH density = 1.3
Table 12 Stock Volumes to Add (mL)
Sample rHSA Sodium NaCI H20
Phosphate
pH 8.6, 150 mM Sodium 9.0 0.000 0.023 0.977
pH 6.5, 150 mM Sodium, 25 mM Phosphate 9.0 0.500 0.000 0.500
pH 6.5, 200 mM Sodium, 25 mM Phosphate 9.0 0.500 0.059 0.441
pH 6.5, 250 mM Sodium, 25 mM Phosphate 9.0 0.500 0.159 0.341
pH 6.5, 300 mM Sodium, 25 mM Phosphate 9.0 0.500 0.259 0.241
pH 6.5, 350 mM Sodium, 25 mM Phosphate 9.0 0.500 0.359 0.141
The dilution was performed by first mixing the albumin and buffer as a bulk
and then
adjusting it to the correct pH by the addition of 1 M HCI. This was then
divided into appropriate
31
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
sized aliquots and water and 5 M NaCI added as required. This ensured that all
samples were
at exactly the same pH.
mL of each sample was then sterile filtered into a baked 10 mL glass vial
stopped
with a sterile butyl rubber seal and then over-sealed. A TO sample of ¨200 pL
was then taken
5 and the vial placed in a water bath that was set at 40 C. Samples (-200
pL) were then taken
from each of the vials after 14 days, diluted 2 fold and injected in
triplicate on the GP-HPLC
system.
The GP-HPLC system was run, by injecting (25 pL) onto a 7.8 mm id x 300 mm
length
TSK G3000SWxL column (Tosoh Bioscience), with a 6.0 mm id x 40 mm length TSK
SW guard
10 column (Tosoh Bioscience). Samples were chromatographed in 25 mM sodium
phosphate, 100
mM sodium sulphate, 0.05% (w/v) sodium azide, pH 7.0 at 1 mL/min and monitored
by UV
detection at 280 nm. Monomer, dimer, trimer and polymer content were
quantified as % w/w by
their respective peak area relative to the total peak area. Results from the
triplicate injections
were averaged to get a mean result for each sample.
Results: The data for the 14 day time point for monomer (Fig. 7) and polymer
(Fig. 8) were
plotted against sodium concentration.
Conclusions:
= The formulation at pH 6.5 was significantly better than that at pH 8.6
used for albumin
batch 1401. The level of polymer significantly increased at pH 8.6, rising to
approximately 20%
after 2 weeks at 40 C compared to ¨2% for the same sodium concentration at pH
6.5.
= The proposed trend of increasing sodium increasing albumin stability
observed with the
screening assay is confirmed here for soluble aggregates with a significant
trend of reduced
polymer formation with increasing sodium concentration. Going from 150 mM, a
standard
albumin concentration due to it being close to physiological conditions, to
200 mM sodium the
level of polymer decreases by >2 fold with then a further decrease of ¨2 fold
going from 200 to
250 mM. Although the polymer decreases even further with higher salt
concentrations up to
350 mM (and potentially beyond) the rate of decrease is slower. These results
are matched in
an increase in monomer remaining with increased sodium. Overall there is a > 4
fold decrease
in polymer formation going from 150 to 250 mM sodium. Consequently, a
preferred albumin
formulation is 25 mM phosphate buffer pH 6.5, 250 mM sodium. The phosphate is
present to
aid pH control. Notably, sodium will come from both sodium chloride and sodium
phosphate
32
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
(including any NaOH used to ensure the pH of the phosphate is correct) and
therefore the buffer
is not 250 mM NaCI.
= Although this work has all been performed with sodium, similar monovalent
or bivalent
metal ions are expected to have a similar effect. However, sodium is a
preferred metal ion
because it is known to be compatible with stem cell culture.
Example 5: Effect of albumin concentration and sodium ion concentration on
stability of
albumin
Method: A sample of purified albumin containing low octanoate (-0.2 mM
octanotae, 100 g/L
albumin) was diafiltered against a minimum of 10 continuous volumes of 25 mM
phosphate, 50
mM sodium pH 6.5 and then concentrated to 338 g/L using a 10 KDa Pall Omega
crossflow UF
to generate a 50 mM sodium starting material. The sample was then diluted with
water, 5 M
NaCI and 0.5 M sodium phosphate pH 6.5 as shown in Table 13:
Table 13 Sample details Volume of stock required (mL)
Sample rHSA rHSA Sodium Phosphate NaCI (5
Na( mM)
Water
(mg/mL) (338 g/L) (0.5 M, pH 6.5) M)
1 100 50 1.78 0.21 0.01 4.00
2 100 100 1.78 0.21 0.07 3.94
3 100 150 1.78 0.21 0.13 3.88
4 100 200 1.78 0.21 0.19 3.82
5 100 250 1.78 0.21 0.25 3.76
6 100 300 1.78 0.21 0.31 3.70
7 100 400 1.78 0.21 0.43 3.58
8 100 500 1.78 0.21 0.55 3.46
9 150 50 2.67 0.17 0.01 3.16
10 150 100 2.67 0.17 0.07 3.10
11 150 150 2.67 0.17 0.13 3.04
12 150 200 2.67 0.17 0.19 2.98
13 150 250 2.67 0.17 0.25 2.92
14 150 300 2.67 0.17 0.31 2.86
150 400 2.67 0.17 0.43 2.74
16 150 500 2.67 0.17 0.55 2.62
33
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Table 13 Sample details Volume of stock required (mL)
Sample rHSA rHSA Sodium Phosphate NaCI (5
Na+ (mM)
Water
(mg/mL) (338 g/L) (0.5 M, pH 6.5) M)
17 200 50 3.56 0.12 0.01
2.32
18 200 100 3.56 0.12 0.07
2.26
19 200 150 3.56 0.12 0.13
2.20
20 200 200 3.56 0.12 0.19
2.14
21 200 250 3.56 0.12 0.25
2.08
22 200 300 3.56 0.12 0.31
2.02
23 200 400 3.56 0.12 0.43
1.90
24 200 500 3.56 0.12 0.55
1.78
25 250 50 4.44 0.08 0.00
1.47
26 250 100 4.44 0.08 0.06
1.41
27 250 150 4.44 0.08 0.12
1.35
28 250 200 4.44 0.08 0.18
1.29
29 250 250 4.44 0.08 0.24
1.23
30 250 300 4.44 0.08 0.30
1.17
31 250 400 4.44 0.08 0.42
1.05
32 250 500 4.44 0.08 0.54
0.93
The samples were then aseptically filtered (0.22 pm filter) into sterile 5 mL
glass vials
and the vials placed in a 40 C incubator for 4 weeks. An aliquot from each
sample was taken
out at intervals, diluted to 40 g/L with water and assayed for soluble
aggregates by GP-HPLC as
per Example 4.
Results: Figure 11 shows monomer levels after a 4 week incubation. A higher
monomer
content shows better stability.
Conclusions:
= All points follow a trend apart from the 150 g/L albumin, 100 mM sodium
sample. It is
unclear why this sample is out of trend but is likely to be an outlier and
does not detract from the
overall conclusions of the experiment.
34
CA 02838964 2013-12-09
WO 2013/006675
PCT/US2012/045505
= For all albumin concentrations tested, there is a clear correlation of
increasing monomer
content i.e. increasing stability with increasing sodium content.
= The majority of the improved stability comes with increasing the sodium
ion
concentration up to ¨200 mM. Above this concentration, although there is some
further
increase in stability it has mostly levelled off. Consequently the optimum
sodium ion
concentration is 200 mM or higher.
Example 6: Effect of different cations on stability of albumin
Method: A sample of purified albumin containing low octanoate (-0.2 mM 100
g/L albumin)
was diluted initially to 50 mg/mL with water such that it contained 50 mg/mL
albumin, 75 mM
NaCI and no pH buffer constituent. The pH was adjusted with 0.5 M HCI to pH
6.43, the amount
of HCI added was insignificant and would not have altered the albumin or other
constituent
concentrations. The samples were then diluted further to 10 mg/mL in UV
transparent microtitre
plate wells using 1 M cation stocks (KCI, NH4CI, CaCl2, MgCl2, NaCI) as shown
in Table 14.
Table 14 Sample parameters Stock Volumes to Add (pL)
Final Vol rHSA rHSA (50 Cation (1
Cation (mM) Na + (mM)
Water
(pL) (mg/mL) g/L) M)
A 50 mM 250 10 50 50.0 8.75 191.3
B 100 mM 250 10 100 50.0 21.25 178.8
C 150 mM 250 10 150 50.0 33.75 166.3
D 200 mM 250 10 200 50.0 46.25 153.8
E 250 mM 250 10 250 50.0 58.75 141.3
F 300 mM 250 10 300 50.0 71.25 128.8
G 400 mM 250 10 400 50.0 96.25 103.8
H 500 mM 250 10 500 50.0 121.25 78.8
Samples for each of KCI, NH4CI, CaCl2, MgCl2, NaCI were prepared according to
Table
14. Therefore, in total, 40 different samples were prepared. Each sample was
tested in
duplicate on a microtitre plate.
The microtitre plate was gently rocked to mix the contents of each well,
centrifuged to
remove any air bubbles and placed in a Biotek Synergy Mx (Potton, UK) plate
reader that had
been pre-equilibrated and controlled at 65 C. The plate was then read at 350
nm every minute
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
over a total incubation time of 8 hours. Gen5 software (Biotek software for
the plate reader
version 2.00.18) was used to calculate the time taken for the A350nm
absorbance to increase
by 0.2 adsorption units above a base line. The base line was calculated from
the mean of the
first 5 data points.
Results: Figure 12 shows the time taken for the absorbance of samples to
increase to 0.2 units
above the baseline. A longer time shows better stability.
Conclusions:
= The control using NaCI shows the same trend as per the other examples
i.e. increasing
sodium levels improves the stability. This confirms that this microtitre plate
method is suitable
for testing stability effects.
= For all the different cations, both single and dual valency (group 1
metals and group 2
metals, respectively) there was a clear increase in albumin stability with
increasing cation
concentration up to 500 mM and probably beyond.
= These data indicate that while all cations improve stability albumin,
MgCl2 is very good.
Example 7: Effect of different anions on the stability of albumin
Method: A sample of purified albumin containing a low concentration of
octanoate (-0.2 mM,
100 g/L albumin) was diluted initially to 50 mg/mL with water such that it
contained 50 mg/mL
albumin, 75 mM NaCI and no pH buffer constituent. The sample was pH adjusted
with 0.5 M
HCI to 6.43, the amount of HCI added was insignificant and would not have
altered the albumin
or constituent concentrations. 1 M sodium anion stock solutions were prepared
according to
Table 15.
36
CA 02838964 2013-12-09
WO 2013/006675
PCT/US2012/045505
Table 15: Anion stocks
Number Components added to water to a
Sodium
Anion Stock MW* of of Na final volume of 100 mL
ion
Solution chemical atoms in Mass Chemical
27% NaOH (mL) (mM)
chemical (g)
NaCI 58.44 1 5.84 0.0
1000
Na2SO4 142.04 2 7.12 0.0
1003
NaH2PO4.2H20 156.02 1 15.61 6.2
1545
_
Trisodium
citrate 294.1 3 9.80 0.0
1000
Na Acetate 136.08 1 13.61 0.0
1000
*MW: molecular weight
The albumin and anion stocks were used as detailed below, being made to a
final
volume of 1 mL in a polystyrene cuvette (Sarstedt 10x4x45 mm). The samples
were gently
mixed prior to the cuvettes being placed into a temperature controlled
spectrophotometer that
had been pre-equilibrated and controlled at 65 C. The absorbance at 350 nm,
referenced
against an empty cuvette, was then monitored over a 2 hour period with a
reading taken every
30 seconds. The data was processed by taking the first 9 data points (¨ the
first 4 minutes),
calculating the mean (average) and then subtracting this from all data points
in order to give a
baseline absorbance. The time taken for the absorbance to increase by 0.1 AU
above this
baseline was recorded for that particular sample. If the absorbance did not go
above 0.1 AU in
2 hours (7200 seconds), then the data was extrapolated in order to get an
approximate time.
Samples for which the absorbance does not go above 0.1 AU in 2 hours are
significantly
improved in stability compared to samples having lower cation concentrations.
A six cuvette holder in the spectrophotometer was used with the first sample
always
being a control and the other five samples using an increasing excipient (i.e.
test material such
as NaCI, Na2SO4) concentration. The control was always a pH 6.5 sample
containing 250 mM
NaCI, this needed to remain in solution with no insoluble aggregates over the
full 2 hour 65 C
incubation for the test to be considered to be valid.
37
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Table 16:
Sample parameters (final
Stock Volumes to Add (pL)
Anion volume = 1000 pL)
Sample concentration and Anion
rHSA rHSA (50
source Na + (mM) * (1 Water
(mg/mL) mg/mL)
M)
1 50 mM NaCI 10 50 200 35.0 765.0
2 150 mM NaCI 10 150 200 135.0 665.0
3 200 mM NaCI 10 200 200 185.0 615.0
4 250 mM NaCI 10 250 200 235.0 565.0
300 mM NaCI 10 300 200 285.0 515.0
6 400 mM NaCI 10 400 200 385.0 415.0
7 50 mM Na2SO4 10 50 200 34.9 765.1
8 150 mM Na2SO4 10 150 200 134.7 665.3
9 200 mM Na2SO4 10 200 200 184.5 615.5
250 mM Na2SO4 10 250 200 234.4 565.6
11 400 mM Na2SO4 10 400 200 384.0 416.0
12 70 mM NaH2PO4 10 69 200 35.0 765.0
13 220 mM NaH2PO4 10 223 200 134.7 665.3
14 300 mM NaH2PO4 10 300 200 184.5 615.5
380 mM NaH2PO4 10 377 200 234.4 565.6
16 600 mM NaH2PO4 10 608 200 384.0 416.0
17 50 mM Na Citrate 10 50 200 35.0 765.0
18 150 mM Na Citrate 10 150 200 135.0 665.0
19 200 mM Na Citrate 10 200 200 185.1 614.9
250 mM Na Citrate 10 250 200 235.1 564.9
21 400 mM Na Citrate 10 400 200 385.1 414.9
22 50 mM Na Acetate 10 50 200 35.0 765.0
23 150 mM Na Acetate 10 150 200 135.0 665.0
24 200 mM Na Acetate 10 200 200 185.0 615.0
250 mM Na Acetate 10 250 200 235.0 565.0
26 400 mM Na Acetate 10 400 200 384.9 415.1
*Anion stock solutions are described in Table 15
38
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
For the citrate samples, the stabilizing effect of the sodium was inconclusive
when
measuring the insoluble aggregates as detected by the A350nm absorbance
increase.
Therefore after the 2 hour, 65 C incubation in the spectrophotometer, the
samples were
removed, centrifuged to remove any large particles and the samples were
analyzed for soluble
aggregates by GP-HPLC (as per Example 4). The data was expressed as c1/0
monomeric
albumin remaining (the higher the value the more stable the formulation). This
was also done
for the phosphate samples.
Results: All controls were valid. Figure 13 shows the effect of sodium ion
concentration and
anion species on the time taken for the A350 absorbance to increase to 0.1 AU
above the base
line. Figure 14 shows, the effect of citrate, phosphate and sodium on the
stability of albumin
following a 65 C, 2 hour incubation. A higher monomer level shows a higher
stability. The
results for the pH 6.5 controls (250 mM sodium) run at the same time gave a
mean result of
81% monomer content.
Conclusions:
= Sodium chloride (sodium salt of an inorganic acid), sodium sulphate
(sodium salt of a
divalent acid) and sodium acetate (sodium salt of an organic acid) all gave a
strong increase in
albumin stability with increasing sodium concentration.
= For sodium dihydrogen phosphate the trend was not as strong as sodium
chloride,
sodium sulphate and sodium acetate. However, at 150 mM and above there is an
increasing
trend of stability with increasing sodium content. This trend was confirmed
when the soluble
aggregates were measured as shown by the strong trend of increasing monomer
remaining with
increasing sodium concentration.
= The trend of increasing stability with increasing sodium concentration
for the sodium
phosphate samples continued through to 600 mM sodium and would probably
continue to
higher sodium concentrations.
= For sodium citrate there was no obvious trend in albumin stability with
sodium
concentration as measured by the A350nm absorbance for the presence of
insoluble
aggregates. However, when the samples (after incubation at 65 C for 2 hours)
were assessed
for soluble aggregates through the measurement of % monomer content remaining
by GP-
HPLC then there was a trend. At 200 mM sodium and below, the monomer content
was fairly
flat but as the sodium content increased above 200 mM there was a definite
trend of increasing
monomer content and therefore albumin stability. Citrate is a chelating agent
and therefore the
39
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
sodium present is chelated to the citrate and is unlikely to be as available
to stabilize the
albumin as the sodium provided, for example, by NaCI.
= Consequently, the inventors believe that any sodium salt (or any other
mono or divalent
anion based on the previous example) will impart stability on albumin, with a
trend of increasing
stability with increasing anion concentration.
Example 8: Effect of different buffers on albumin stability
Method: A sample of purified albumin containing a low concentration of
octanoate (-0.2 mM,
100 g/L albumin) was diluted initially to 50 mg/mL with water such that it
contained 50 mg/mL
albumin, 75 mM NaCI and no buffer constituent. The sample was pH adjusted with
0.5 M HCI to
pH 6.43, the amount of HCI added was insignificant and would not have altered
the albumin or
constituent concentrations.
An unbuffered stock of 1 M NaCI together with the following buffers (Table 17)
pH
adjusted to pH 6.43 as per the albumin stock (so that when added to the
albumin the pH would
not change) was prepared. For phosphate the pH was adjusted with 27% NaOH, for
citrate it
was adjusted with citric acid (citric acid powder) and for acetate it was
adjusted with acetic acid
(glacial acetic acid):
Table 17:
Final Number of Mass 27% Buffer
Anion Stock MW of Na
Vol Na atoms in Chemical NaOH Molarity
Solution chemical (mM)
(mL) chemical (g) (mL) (mM)
NaCI 100 58.44 1 5.84 0.0 1000 N/A
NaH2PO4.2H20 100 156.02 1 15.61 6.2 1545 1001
Na Citrate 100 294.1 3 9.80 0.0 1000 333
Na Acetate 100 136.08 1 13.61 0.0 1000 1000
The amount of acid added was insignificant and would not have altered the
albumin or
constituent concentrations.
The albumin and buffer stocks were used as detailed below, being made to a
final
volume of 1 mL in a polystyrene cuvette (Sarstedt 10x4x45 mm). The samples
were gently
mixed prior to the cuvettes being placed into a temperature controlled
spectrophotometer that
had been pre-equilibrated and controlled at 65 C. The absorbance at 350 nm,
referenced
against an empty cuvette, was then monitored over a 2 hour period with a
reading taken every
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
30 seconds. The data was processed by taking the first 9 data points (- the
first 4 minutes),
calculating the mean and then subtracting this from all data points in order
to give a baseline
absorbance. The time taken for the absorbance to increase by 0.1 AU above this
baseline was
recorded for that particular formulation sample. If the absorbance did not go
above 0.1 AU in 2
hours (7200 seconds) then the data was extrapolated in order to get and
approximate time.
A six cuvette holder in the spectrophotometer was used with the first sample
always
being a control and the other five samples using an increasing excipient
concentration. The
control was always a pH 6.5 sample containing 250 mM NaCI, this needed to
remain in solution
with no insoluble aggregates over the full 2 hour 65 C incubation for the test
to be considered to
be valid.
Table 18 Sample parameters Stock Volumes to Add (pL)
Sample (final volume = rHSA Buffer Na + rHSA (50 Buffer NaCI (1
Water
1000 pL) (mg/mL) (mM) (mM) mg/mL) stock* M)
pH 6.4, 50 mM NaCI 10 0 50 20 0.0 35.0
765.0
pH 6.4, 150 mM NaCI 10 0 150 20 0.0 135.0
665.0
pH 6.4, 200 mM NaCI 10 0 200 20 0.0 185.0
615.0
pH 6.4, 250 mM NaCI 10 0 250 200 0.0 235.0
565.0
pH 6.4, 300 mM NaCI 10 0 300 200 0.0 285.0
515.0
pH 6.4, 400 mM NaCI 10 0 400 200 0.0 385.0
415.0
pH 6.4, 50 mM NaH2PO4,
10 50 92 200 50 0.0
750.0
50 mM Na
pH 6.4, 50 mM NaH2PO4,
10 50 150 200 50 57.8 692.2
150 mM Na
pH 6.4, 50 mM NaH2PO4,
10 50 200 200 50 107.8 642.2
200 mM Na
pH 6.4, 50 mM NaH2PO4,
10 50 250 200 50 157.8 592.2
250 mM Na
pH 6.4, 50 mM NaH2PO4,
10 50 400 200 50 307.8 442.2
400 mM Na
pH 6.4, 50 mM Acetate, 50
10 50 65 200 50 0
750.0
mM Na
pH 6.4, 50 mM Acetate, 10 50 150 200 50 85.0
665.0
41
CA 02838964 2013-12-09
WO 2013/006675
PCT/US2012/045505
Table 18 Sample parameters Stock Volumes to Add (pL)
Sample (final volume = rHSA Buffer Na + rHSA (50 Buffer NaCl (1
Water
1000 pL) (mg/mL) (mM) (mM) mg/mL) stock* M)
150 mM Na
pH 6.4, 50 mM Acetate,
50 200 200 50 135.0 615.0
200 mM Na
pH 6.4, 50 mM Acetate,
10 50 250 200 50 185.0 565.0
250 mM Na
pH 6.4, 50 mM Acetate,
10 50 400 200 50 335.0 415.0
400 mM Na
pH 6.4, 50 mM Citrate, 50
10 50 165 200 150.1 0
649.9
mM Na
pH 6.4, 50 mM Citrate, 150
10 50 200 200
150.1 35.0 614.9
mM Na
pH 6.4, 50 mM Citrate, 200
10 50 250 200
150.1 85.0 564.9
mM Na
pH 6.4, 50 mM Citrate, 250
10 50 350 200
150.1 185.0 464.9
mM Na
pH 6.4, 50 mM Citrate, 400
10 50 500 200
150.1 335.0 314.9
mM Na
*Buffer stocks were as per Table 17
Results: All controls were valid. For the samples, the time taken for the A350
absorbance to
increase to 0.1 AU above the base line was plotted against the sodium
concentration. Figure 15
5
shows that for all buffers, albumin stability increases as sodium ion
concentration increases.
For the citrate samples the trend appears offset relative to the other
samples.
Consequently, the data for no buffer (sodium provided only by NaCI) was
plotted together with
the samples buffered with sodium citrate, but with the sodium concentration
coming from the
sodium citrate ignored (Figure 16).
Conclusions:
= For all buffers, and also with no buffer, there is a clear trend of
increasing albumin
stability with increasing sodium concentration.
42
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
= Even with citrate, which did not appear to be as good a sodium donator
for albumin
stability as NaCI, there was a trend of increasing stability within increasing
sodium concentration
but it was offset slightly. The reason for this offset is that, like for all
the buffers, the sodium
from the buffer was used in the calculation of the total sodium content.
Consequently, if this
sodium is not as effective (e.g. available) as sodium from sodium chloride (as
shown in the
previous examples) then there will be an offset. This was confirmed by Figure
16.
= Sodium phosphate is a good pH buffer, but as a donator for sodium for
stabilization
there are better donators and therefore it may be advantageous to combine
sodium phosphate
with another donator of cation (sodium or other cation) to stabilize albumin.
= Consequently, the inventors believe that the buffer in the formulation is
not particularly
important and any buffer, or no buffer, can be used. However, if the buffer is
chelating then the
anion present from the buffer should not be included in the calculation of the
required
concentration of anion.
Example 9: Effect of high salt concentration on stability of albumin variants
Method: Various albumins and variants (Table 19) were diluted with 0.5 M
sodium phosphate
buffer (pH 6.5).The variants were mature HSA (SEQ ID No: 2) with point
mutations (K573P,
K500A, K573Y, K573W) and mouse serum albumin (MSA, SEQ ID No: 19). The rHSA
concentration and sodium ion concentration of the stock solutions of the
albumin variants are
provided in Table 20.
Table 19 Stock Volumes Added (mL) Sample details
Phosphate
Albumin Albumin Phosphate Na Actual
Albumin (0.5 M, pH Water
(mg/mL) (mM) (mM) pH
Variant 6.5)***
HSA-K573P 3.00 1.572 1.716 50.0 125 256 6.50
HSA-K500A 3.00 1.450 1.350 50.0 125 261 6.49
HSA-K573Y 4.50 1.710 0.650 50.0 125 281 6.49
HSA-K573W 4.50 1.520 0.073 50.0 125 293 6.51
HSA-K573H 4.00 1.750 1.250 50.0 125 269 6.50
43
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Table 19 Stock Volumes Added (mL) Sample details
Phosphate
Albumin Albumin Phosphate Na Actual
Albumin (0.5 M, pH Water
** (mg/mL) (mM) (mM) pH
Variant 6.5)***
HSA-K573F 4.00 1.640 0.900 50.0 125 276 6.50
HSA-wild-type* 2.50 1.250 1.250 50.0 125 263 6.50
MSA-wild-type 3.00 1.440 1.310 50.0 125 262 6.48
*HSA wild-type was spiked with 5 pL 2M octanoate (equivalent to 4 mM
octanoate, 100 g/L)
**Albumin: see Table 20
***Phosphate (0.5 M, pH 6.5) is described in Table 20b
Table 20 rHSA Conc (mg/mL) Na (mM)
K573P Stock 104.8 145
K500A Stock 96.7 145
K573Y Stock 76.2 145
K573W Stock 67.7 145
K573H Stock 87.5 145
K573F Stock 81.8 145
HSA Wild-type 100 150
Mouse 95.8 145
Sodium
Table 20b Make up NaH2PO4.2 27% NaOH Na
Phosphate
Buffer Stock Solution Vol (mL) H20 (g) (mL)
(mM)
(mM)
0.5 M Sodium Phosphate pH 6.5 250 19.50 7.0 500
746
As all the variants had been purified slightly differently to the wild type
human albumin,
the levels of octanoate present would have been slightly different for each
variant. From
previous results, it was estimated that the octanoate present in the variants
would have been
equivalent to -4 mM at 100 g/L albumin. As the wild-type stock had negligible
levels of
octanoate present, this stock was subsequently spiked with 5 pL of 2 M
octanoate into the final
44
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
volume to give an approximately equivalent concentration of octanoate,
relative to the variant
albumins.
The albumin stocks and a 1 M NaCI stock were used according to Table 21, each
sample being made to a final volume of 1 mL in a polystyrene cuvette (Sarstedt
10x4x45 mm).
The samples were gently mixed prior to the cuvettes being placed into a
temperature controlled
spectrophotometer that had been pre-equilibrated and controlled at 65 C. The
absorbance at
350 nm, referenced against an empty cuvette, was then monitored over a 2 hour
period with a
reading taken every 30 seconds. The data was processed by taking the first 9
data points (-
the first 4 minutes), calculating the mean (average) and then subtracting this
from all data points
in order to give a baseline absorbance. The time taken for the absorbance to
then increase by
0.1 AU above this baseline was recorded for that particular formulation
sample. If the
absorbance did not go above 0.1 AU in 2 hours (7200 seconds) then the data was
extrapolated
in order to get and approximate time.
A six cuvette holder in the spectrophotometer was used with the first sample
always a
control and the other five samples using an increasing excipient
concentration. The control was
always a pH 6.5 sample containing 250 mM NaCI, this needed to remain in
solution with no
insoluble aggregates over the full 2 hour 65 C incubation for the test to be
considered to be
valid.
Table 21 Actual concentration Stock Volumes to Add (pL)
Sample Albumin rHSA Phosphate Na NaCI
Albumin* Water
Variant (mg/mL) (mM) (mM) (1 M)
1 K573P 10 25 51 200.0 0.0 800.0
2 K573P 10 25 150 200.0 98.9 701.1
3 K573P 10 25 200 200.0 148.9 651.1
4 K573P 10 25 250 200.0 198.9 601.1
5 K573P 10 25 400 200.0 348.9 451.1
6 K500A 10 25 52 199.9 0.0 800.1
7 K500A 10 25 150 199.9 97.7 702.3
8 K500A 10 25 200 199.9 147.7 652.3
9 K500A 10 25 250 199.9 197.7 602.3
10 K500A 10 25 400 199.9 347.7 452.3
11 K573Y 10 25 56 200.1 0.1 799.8
CA 02838964 2013-12-09
WO 2013/006675
PCT/US2012/045505
Table 21 Actual concentration Stock Volumes to Add (uL)
Sample Albumin rHSA Phosphate Na NaCI
Albumin* Water
Variant (mg/mL) (mM) (mM) (1 M)
12 K573Y 10 25 150 200.1 93.8 706.2
13 K573Y 10 25 200 200.1 143.8
656.2
14 K573Y 10 25 250 200.1 193.8
606.2
15 K573Y 10 25 400 200.1 343.8
456.2
16 K573W 10 25 59 200.0 0.0 800.0
17 K573W 10 25 150 200.0 91.4 708.6
18 K573W 10 25 200 200.0 141.4
658.6
19 K573W 10 25 250 200.0 191.4
608.6
20 K573W 10 25 400 200.0 341.4
458.6
21 K573H 10 25 54 200.0 0.0 800.0
22 K573H 10 25 150 200.0 96.1 703.9
23 K573H 10 25 200 200.0 146.1 653.9
24 K573H 10 25 250 200.0 196.1 603.9
25 K573H 10 25 400
200.0 346.1 453.9
26 K573F 10 25 55 199.9 0.0 800.1
27 K573F 10 25 150 199.9 94.9 705.2
28 K573F 10 25 200 199.9 144.9
655.2
29 K573F 10 25 250 199.9 194.9
605.2
30 K573F 10 25 400 199.9 344.9
455.2
31 HSA Wild-
25 53 200.0 0.0 800.0
type
32 HSA Wild-
10 25 150 200.0 97.3 702.7
type
33 HSA Wild-
10 25 200 200.0 147.3
652.7
type
34 HSA Wild-
10 25 250 200.0 197.3
602.7
type
35 HSA Wild-
10 25 400 200.0 347.3
452.7
type
46
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Table 21 Actual concentration Stock Volumes to Add (pL)
Sample Albumin rHSA Phosphate Na NaCI
Albumin* Water
Variant (mg/mL) (mM) (mM) (1 M)
36 Mouse 10 25 52 200.1 0.0 799.9
37 Mouse 10 25 150 200.1 97.5 702.4
38 Mouse 10 25 200 200.1 147.5 652.4
39 Mouse 10 25 250 200.1 197.5 602.4
40 Mouse 10 25 400 200.1 347.5 452.4
*Albumin concentration is provided in Table 20.
Results: All controls were valid. Figure 17 and 18 shows the effect of sodium
ion concentration
on the time taken for the A350 absorbance to increase by 0.1 AU above the base
line.
Conclusions:
= All points follow a trend apart from the wild type albumin, 150 mM sodium
sample. It is
unclear why this point is out of trend but is likely to be an outlier and does
not detract from the
overall conclusions.
= For all albumin variants there is a clear trend of increasing albumin
stability with
increasing sodium concentration.
= Mature mouse serum albumin (SEQ ID No: 19) is 72.1% identical (using the
algorithim
described herein) to mature wild-type human serum albumin (SEQ ID NO: 2) and
even though
the overall stability was not as high as HSA, or HSA variants, there was still
a clear trend of
increasing stability with increasing sodium concentration at and above 200 mM.
= It is difficult to say whether or not there is a significant difference
in stability between the
different variants because it is difficult to compare the stabilities of the
variants to the stability of
wild type albumin since the base formulation with respect to the level of
octanoate present was
not absolutely controlled to be the same between each variant. However, within
the data sets
for each variant the level of octanoate will be the same and therefore the
increase in stability
can only be due to the increasing level of sodium.
= The one sample where the octanoate was known (wild type human serum
albumin,
equivalent to 4 mM at 100 g/L albumin) shows that the observed stability
increase with sodium
is also valid at this level of octanoate.
47
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Example 10: Effect of pH on albumin stability
Method: A sample of purified albumin containing low octanoate (-0.2 mM, 100
g/L albumin)
was diluted initially to 50 mg/mL according to Table 22, using phosphate
stocks according to
Table 23.
Table 22 Stock Volumes Added (mL) Final parameters of sample
Sodium
pH of rHSA rHSA Sodium
Phosphate Na
Sample phosphate (50 Water Conc Phosphate
buffer (0.5 (mM)
buffer mg/mL) M)* (mg/mL) (mM)
1 pH 5.0 2.50 1.25 1.25 50.0 125 204
2 pH 6.5 2.50 1.25 1.25 50.0 125 261
3 pH 7.0 2.50 1.25 1.25 50.0 125 288
4 pH 8.0 2.50 1.25 1.25 50.0 125 318
*Sodium phosphate buffer stock solutions are described in Table 23
Table 23:
Components (made up to a final
Buffer parameters
volume of 250 mL with water)
Buffer Stock Solution 27% Na
Phosphate
NaH2PO4.2H20 (g) NaOH Molarity
(mM)
(mL) (mM)
0.5 M Phosphate pH 5 19.50 0.5 500 518
0.5 M Phosphate pH 6 19.51 3.8 500 634
0.5 M Phosphate pH 7 19.50 10.0 500 851
0.5 M Phosphate pH 8 19.50 13.4 500 970
0.5 M Phosphate pH 6.5 19.50 7.0 500 746
The samples were pH adjusted with 0.5 M HCI (i.e. no added sodium) to give
final pHs
of 5.02 and 5.55 using the pH 5 stock, pHs of 6.00 and 6.49 using the pH 6.5
stock, pH of 7.04
48
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
using the pH 7 stock and pHs of 7.55 and 7.98 using the pH 8 stock. The amount
of HCI added
was insignificant and would not have altered the albumin or constituent
concentrations.
The stocks were used as detailed below (Table 24), being made to a final
volume of 1
mL in a polystyrene cuvette (Sarstedt 10x4x45 mm). The samples were gently
mixed prior to
the cuvettes being placed into a temperature controlled spectrophotometer that
had been pre-
equilibrated to and controlled at 65 C. The absorbance at 350 nm, referenced
against an empty
cuvette, was then monitored over a 2 hour period with a reading taken every 30
seconds. The
data was processed by taking the first 9 data points (- the first 4 minutes),
calculating the mean
(average) and then subtracting this from all data points in order to give a
baseline absorbance.
The time taken for the absorbance to then increase by 0.1 AU above this
baseline was recorded
for that particular formulation sample. If the absorbance did not go above 0.1
AU in 2 hours
(7200 seconds) then the data was extrapolated in order to get and approximate
time.
A six cuvette holder in the spectrophotometer was used with the first sample
always
being a control and the other five samples using an increasing excipient
concentration. The
control was always a pH 6.5 sample containing 250 mM NaCI, this needed to
remain in solution
with no insoluble aggregates over the full 2 hour 65 C incubation for the test
to be considered to
be valid.
Table 24 Actual Stock Volumes to
Add
(pL)
Sample rHSA
Final rHSA
Number Phosph Na (50 NaCI
Na Vol (mg/m
Water
pH ate (mM) (mM) mg/ (1 M)
(mM) (pL) L)
mL)*
1 6.49 50 1000 10 25 52
200.0 0.0 800.0
2 6.49 150 1000 10 25 150
200.0 97.7 702.3
3 6.49 200 1000 10 25
200 200.0 147.7 652.3
4 6.49 250 1000 10 25
250 200.0 197.7 602.3
5 6.49 400 1000 10 25 400
200.0 347.7 452.3
6 5.02 50 1000 10 25 50
200.0 9.1 790.9
7 5.02 150 1000 10 25
150 200.0 109.1 690.9
8 5.02 200 1000 10 25
200 200.0 159.1 640.9
9 5.02 250 1000 10 25 250
200.0 209.1 590.9
49
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
Table 24 Actual Stock
Volumes to Add
(pL)
Sample rHSA
Final rHSA
Number Phosph Na (50 NaCl
Na Vol (mg/m Water
pH ate (mM) (mM) mg/ (1 M)
(mM) (pL) L)
mL)*
5.02 400 1000 10 25 400 200.0 359.1
440.9
11 5.55 50 1000 10 25 50 200.0
9.1 790.9
12 5.55 150 1000 10 25 150
200.0 109.1 690.9
13 5.55 200 1000 10 25 200
200.0 159.1 640.9
14 5.55 250 1000 10 25 250 200.0
209.1 590.9
5.55 400 1000 10 25 400 200.0 359.1
440.9
16 6.00 50 1000 10 25 52 200.0
0.0 800.0
17 6.00 150 1000 10 25 150 200.0
97.7 702.3
18 6.00 200 1000 10 25 200 200.0
147.7 652.3
19 6.00 250 1000 10 25 250 200.0
197.7 602.3
6.00 400 1000 10 25 400 200.0 347.7
452.3
21 7.04 50 1000 10 25 58 200.0
0.0 800.0
22 7.04, 150 1000 10 25 150
200.0 92.5 707.6
23 7.04 200 1000 10 25 200 200.0
142.5 657.6
24 7.04 250 1000 10 25 250 200.0
192.5 607.6
7.04 400 1000 10 25 400 200.0 342.5
457.6
26 7.55 50 1000 10 25 64 200.0
0.0 800.0
27 7.55 150 1000 10 25 150
200.0 86.5 713.5
28 7.55 200 1000 10 25 200 200.0
136.5 663.5
29 7.55 250 1000 10 25 250 200.0
186.5 613.5
7.55 400 1000 10 25 400 200.0 336.5
463.5
31 7.98 50 1000 10 25 64 200.0
0.0 800.0
32 7.98 150 1000 10 25 150 200.0
86.5 713.5
33 7.98 200 1000 10 25 200 200.0
136.5 663.5
34 7.98 250 1000 10 25 250 200.0
186.5 613.5
7.98 400 1000 10 25 400 200.0 336.5
463.5
*Albumin stocks are described in Table 23.
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
For the pH 7 (measure pH 7.04), 7.5 (measured pH 7.55) and 8 (measure pH 7.98)
samples the stabilizing effect of the sodium was inconclusive when measuring
insoluble
aggregates as detected by the A350nm absorbance increase. Therefore after the
2 hour
incubation at 65 C incubation in the spectrophotometer the samples were
removed, centrifuged
to remove any large particles and the samples analyzed for soluble aggregates
by GP-HPLC
(as per Example 4). The data was expressed as % monomeric albumin remaining
(the higher
the value the more stable the formulation).
Results: All controls were valid. Figures 19, 20 and 21 show the stability of
albumin relative to
sodium ion concentration. The results for the pH 6.5 controls run at the same
time as the pH7,
7.5 and 8 samples gave a mean of 82% monomer content.
Conclusions:
= For all pHs from pH 5 to pH 6.5 it was clear that there was an increase
in albumin
stability with increasing albumin concentration as measured by the A350
absorbance increase
(insoluble aggregates).
= At pHs 7, 7.5 and 8 the trend was not clear (Figure 19) with a possible
dip in stability
around 150 mM Na. However, when these samples were analyzed by GP-HPLC for
soluble
aggregates and % monomer remaining (Figure 21) there was a clear trend of
increasing stability
with increasing sodium. The reason that this trend was not observed for the
insoluble
aggregates may be due to the fact that these pHs are the furthest from the pl
of albumin (5.2 for
albumin) and therefore they are less likely to precipitate with the aggregates
coming out of
solution.
= The pH 6.5 controls had higher levels of monomer remaining at the same
sodium ion
concentration (250 mM) than any of the higher pHs showing that pH 6.5 is the
more stable pH
for albumin.
= Combining both the insoluble and soluble aggregate data shows that
increasing sodium
concentration increases albumin stability from pH 5 to pH 8.
Example 11: Effect of Octanoate on Stem Cell Cultures
Method: The effect of octanoate on stem cell culture was carried out by a
contract research
organization: Cellartis AB (Gothenburg, Sweden). Briefly, albumin at 100 g/L
with varying levels
of octanoate (0.2, 0.5, 1.0 and 8.0 mM) was used as the albumin supplement in
standard stem
51
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
cell culture media. Human embryonic stem cells (cell lines SA121 and SA181
(Cellartis AB, cell
lines deposited in the European Human Embryonic Stem Cell Registry)) were
transferred from
their standard media and grown through 5 passages in 6 well plates in the
media supplemented
with the albumin containing varying levels of octanoate. The cell growth over
the 5 passages
was assessed by monitoring the cell doubling times during consecutive passages
in cell
production. The doubling times of cultures should be within a range of 28-40
hours, and can be
seen as a trend indicator. In order to determine the undifferentiation state
of the cells after 5
passages in albumin supplemented media, antibodies against four different
accepted markers
for the undifferentiated state, namely Oct-4, SSEA-3, Tra-1 60 and hES-
Cellect, were used for
immunostaining.
Results: Table 25 shows data for the doubling time. The initial doubling times
are quite high,
probably due to cells needing to adjust to the new culture medium composition.
However, the
doubling times between passages 2 and 4 are all within expected range except
for the sample
containing 8 mM octanoate which failed to maintain acceptable cell attachment
and could not be
continued past passage 2 even with modified medium and coating conditions.
Doubling times
for passage 5 were highly variable and for some samples lay considerably
outside the standard
range. However, it is difficult to draw conclusions as cultures were not
expanded further.
Table 25: Doubling time in hours for each of the cell lines over five
passages. Doubling time is
presented in hours, and formula used is Td(h) = T * LOG2/LOG(cells
harvested/cells seeded). T
= time in hours between passages
Octanoate
Cell line Passage 1 Passage 2 Passage 3 Passage 4 Passage 5
Present (mM)
0.2 45.6 31.7 35.8 33.8 56.1
SA121 0.5 44.5 36.5 42.3 44.9 30.4
1.0 65.5 33.4 31.2 30.4 38.7
8.0 61.8 46.0
0.2 88.5 31.9 31.5 29.5 452
SA181 0.5 144.0 34.3 37.3 29.0 134
1.0 47.1 32.8 36.9 31.4 59.4
8.0 117 89.7
Table 26 shows data for the immunocytochemical stainings for differentiation
markers
and shows that all the samples (except the sample containing 8 mM octanoate,
since it did not
52
CA 02838964 2013-12-09
WO 2013/006675 PCT/US2012/045505
reach 5 passages) supported cultures to maintain an undifferentiated state for
the 5 passages
tested.
Table 26: Summary of immunocytochemical staining performed on cells stained
using
antibodies against Oct-4, Tra-1 60, SSEA-3, hES-CellectTM and SSEA-1. (+++)
represents good
staining and easy to detect, while (-) represents no staining detectable.
Octanoate hES-
Cell line Oct-4 Tra-1 60 SSEA-3
SSEA-1
Present (mM) CellectTM
0.2 +++ +++ +++ +++
SA121 0.5 +++ +++ +++ +++
1.0 +++ +++ +++ +++
0.2 +++ +++ +++ +++
SA181 0.5 +++ +++ +++ +++
1.0 +++ +++ +++ +++
Conclusions:
= The octanoate level present in the albumin is important for stem cell
attachment,
maintenance of undifferentiated cell growth. At 8 mM octanoate in 100 g/L
albumin the
octanoate is toxic to stem cells and does not allow their attachment to
surfaces or cell growth.
The invention described and claimed herein is not to be limited in scope by
the specific
aspects herein disclosed, since these aspects are intended as illustrations of
several aspects of
the invention. Any equivalent aspects are intended to be within the scope of
this invention.
Indeed, various modifications of the invention in addition to those shown and
described herein
will become apparent to those skilled in the art from the foregoing
description. Such
modifications are also intended to fall within the scope of the appended
claims. In the case of
conflict, the present disclosure including definitions will control.
53
